Variability in the clinical pattern of cutaneous side-effe symptoms: does a DRESS syndrome really exist?

British Journal of Dermatology 156, 609-611 DOI: 10.1111/j.1365-2133.2006.07704.x

Citation Report

#	ARTICLE	IF	CITATIONS
1	Acute Generalized Exanthematous Pustulosis. American Journal of Pathology, 2002, 161, 2079-2086.	1.9	145
3	Treatment of Epidermal Necrolysis with High-Dose Intravenous Immunoglobulins (IVIg). Drugs, 2005, 65, 2085-2090.	4.9	73
9	Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?. British Journal of Dermatology, 2007, 156, 609-611.	1.4	1,257
10	Use and safety profile of antiepileptic drugs in Italy. European Journal of Clinical Pharmacology, 2007, 63, 409-415.	0.8	22
11	Stevens-Johnson syndrome and toxic epidermal necrolysis. Current Allergy and Asthma Reports, 2007, 7, 243-247.	2.4	27
12	Evaluation and management of pediatric drug allergic reactions. Current Allergy and Asthma Reports, 2007, 7, 402-409.	2.4	6
13	Hydroxychloroquine-induced DRESS syndrome. Clinical Rheumatology, 2008, 27, 537-539.	1.0	40
14	Probable drug rash with eosinophilia and systemic symptoms syndrome related to tetrazepam. Journal of the European Academy of Dermatology and Venereology, 2008, 22, 887-889.	1.3	7
15	DRESS syndrome induced by sodium meglumine ioxitalamate. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 786-787.	2.7	14
16	Toxic Epidermal Necrolysis Clinical Guidelines. Journal of Burn Care and Research, 2008, 29, 706-712.	0.2	71
17	Acute Generalized Exanthematous Pustulosisafter Ingestion of Lacquer Chicken. Annals of Dermatology, 2008, 20, 209.	0.3	4
18	Drug-Induced Hypersensitivity Syndrome. Medicine (United States), 2009, 88, 131-140.	0.4	168
19	Severe drugâ€induced skin reactions: clinical pattern, diagnostics and therapy. JDDG - Journal of the German Society of Dermatology, 2009, 7, 142-162.	0.4	66
20	Flareâ€up of patch test of trimethoprim–sulfamethoxazole (coâ€trimoxazole) during oral desensitization. Contact Dermatitis, 2009, 61, 50-51.	0.8	8
21	Delayed hypersensitivity to bosentan. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 499-501.	2.7	8
22	Anaphylaxis to amidotrizoate proved by skin testing and flow cytometryâ€based basophil activation test. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 501-502.	2.7	15
23	Strontium ranelateâ€induced DRESS syndrome: first two case reports. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 658-659.	2.7	45
24	Patch Testing for the Diagnosis of Anticonvulsant Hypersensitivity Syndrome. Drug Safety, 2009, 32, 391-408.	1.4	60

ATION RED

#	Article	IF	CITATIONS
30	Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity. Osteoporosis International, 2010, 21, 723-732.	1.3	61
31	Epicutaneous patch testing in drug hypersensitivity syndrome (DRESS). Contact Dermatitis, 2010, 62, 47-53.	0.8	167
32	The spectrum of histopathological features in acute generalized exanthematous pustulosis: a study of 102 cases. British Journal of Dermatology, 2010, 163, 1245-1252.	1.4	82
33	Stevens-Johnson syndrome and toxic epidermal necrolysis due to anticonvulsants share certain clinical and laboratory features with drug-induced hypersensitivity syndrome, despite differences in cutaneous presentations. Clinical and Experimental Dermatology, 2010, 35, 723-728.	0.6	30
34	Propylthiouracilâ€induced DRESS syndrome confirmed by a positive patch test. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 407-409.	2.7	14
35	Cutaneous drug reactions. , 2010, , 511-523.e8.		1
36	Drug Reaction With Eosinophilia and Systemic Symptoms. Archives of Dermatology, 2010, 146, 1373.	1.7	274
37	Failure to Recognize and Manage Patients With DRESS. Archives of Dermatology, 2010, 146, 1379.	1.7	2
38	Bosentan-Induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome: Figure 1 Journal of Rheumatology, 2010, 37, 1077.1-1078.	1.0	11
41	Le syndrome d'hypersensibilité (DRESS) n'est qu'une maladie virale. Revue Francaise D'allergologie, 2010, 50, 171-173.	0.1	15
42	Retrospective analysis of drug-induced hypersensitivity syndrome: A study of 27 patients. Journal of the American Academy of Dermatology, 2010, 63, 219-227.	0.6	83
43	Drug Allergy: An Updated Practice Parameter. Annals of Allergy, Asthma and Immunology, 2010, 105, 259-273.e78.	0.5	817
47	Management of side-effects. Clinics and Research in Hepatology and Gastroenterology, 2011, 35, S69-S74.	0.7	8
50	HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans. New England Journal of Medicine, 2011, 364, 1134-1143.	13.9	815
52	The DRESS Syndrome: A Literature Review. American Journal of Medicine, 2011, 124, 588-597.	0.6	788
53	latrogenic skin injury in hospitalized patients. Clinics in Dermatology, 2011, 29, 622-632.	0.8	18
55	Severe Drug-Induced Skin Reactions: Clinical Pattern, Diagnostics and Therapy. , 2011, , .		10
56	An unusual case of DRESS syndrome due to leflunomide. BMJ Case Reports, 2011, 2011, bcr0620114330.	0.2	10

#	Article	IF	Citations
57	SEVERE, ACUTE ADVERSE CUTANEOUS DRUG REACTIONS II: DRESS SYNDROME AND SERUM SICKNESS-LIKE REACTION. , 0, , 162-167.		0
58	The epidemiology and treatment of gout. Open Access Rheumatology: Research and Reviews, 2011, 3, 73.	0.8	10
59	Plastered in pustules. BMJ: British Medical Journal, 2011, 342, d926-d926.	2.4	1
60	Identifying prognostic factors for drug rash with eosinophilia and systemic symptoms (DRESS). European Journal of Dermatology, 2011, 21, 930-937.	0.3	43
61	Case of drug rash with eosinophilia and systemic symptoms induced by zonisamide and reactivation of human herpes virus 7. Journal of Dermatology, 2011, 38, no-no.	0.6	3
62	Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking. Clinical and Experimental Dermatology, 2011, 36, 6-11.	0.6	192
63	Follicular mucinosis in a mycosis fungoides-like hypersensitivity syndrome induced by oxcarbamazepine. Journal of Cutaneous Pathology, 2011, 38, 1009-1011.	0.7	9
64	Drug reaction with eosinophilia and systemic symptoms induced by carbamazepine: DRESSed to kill. General Hospital Psychiatry, 2011, 33, 412.e5-412.e8.	1.2	7
65	Risk factors associated with DRESS syndrome produced by aromatic and non-aromatic antipiletic drugs. European Journal of Clinical Pharmacology, 2011, 67, 463-470.	0.8	40
67	DRESS syndrome à la carbamazépine avec réactivation du cytomégalovirus. Reanimation: Journal De La Societe De Reanimation De Langue Francaise, 2011, 20, 251-254.	0.1	1
68	Severe hypersensitivity reaction as acute eosinophilic pneumonia and skin eruption induced by proguanil. European Respiratory Journal, 2011, 37, 1526-1528.	3.1	7
69	Severe cutaneous adverse reactions to antiepileptic drugs in Asians. Neurology, 2011, 77, 2025-2033.	1.5	97
70	Drug fever and DRESS syndrome. British Journal of Hospital Medicine (London, England: 2005), 2011, 72, 224-228.	0.2	1
71	Multiple Follicular Pustules as an Atypical Cutaneous Manifestation of Drug-induced Hypersensitivity Syndrome. Acta Dermato-Venereologica, 2011, 91, 728-729.	0.6	2
72	Severe cutaneous adverse reactions. Indian Journal of Dermatology, Venereology and Leprology, 2011, 77, 3.	0.2	11
73	Drug rash with eosinophilia and systemic symptoms (DRESS) after an unrelated donor BM transplant. Bone Marrow Transplantation, 2011, 46, 1487-1488.	1.3	1
74	Cephazolin-Induced Toxic Epidermal Necrolysis Treated with Intravenous Immunoglobulin and N-Acetylcysteine. Case Reports in Immunology, 2012, 2012, 1-4.	0.2	7
75	Intravenous immunoglobulin in the treatment of drug rash eosinophilia and systemic symptoms caused by phenytoin. Annals of Indian Academy of Neurology, 2012, 15, 320.	0.2	9

#	Article	IF	CITATIONS
76	Six-year Retrospective Review of Drug Reaction with Eosinophilia and Systemic Symptoms. Acta Dermato-Venereologica, 2012, 92, 200-205.	0.6	39
77	High-dose Intravenous Immunoglobulin Monotherapy for Drug-induced Hypersensitivity Syndrome. Acta Dermato-Venereologica, 2012, 92, 100-101.	0.6	39
78	Levetiracetam-Induced Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome. Annals of Pharmacotherapy, 2012, 46, e20-e20.	0.9	32
79	Poor Benefit/Risk Balance of Intravenous Immunoglobulins in DRESS. Archives of Dermatology, 2012, 148, 543.	1.7	96
80	Initial Presentation of DRESS: Often Misdiagnosed as Infections. Archives of Dermatology, 2012, 148, 1085.	1.7	16
81	Mechanisms in cutaneous drug hypersensitivity reactions. , 2012, , 78-92.		5
82	Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) Probably Induced by Cefotaxime: a Report of Two Cases. Clinical Medicine and Research, 2012, 10, 32-35.	0.4	13
83	Epidemiology of Cutaneous Adverse Drug Reactions. Chemical Immunology and Allergy, 2012, 97, 1-17.	1.7	71
84	Drug-induced hypersensitivity syndrome: recent advances in drug allergy. Expert Review of Dermatology, 2012, 7, 539-547.	0.3	7
85	A Case of Drug Reaction with Eosinophilia and Systemic Symptoms. Case Reports in Medicine, 2012, 2012, 1-4.	0.3	2
86	Alternative Procedure to Allow Continuation of Dapsone Therapy despite Serious Adverse Reaction in a Case of Dapsone-Sensitive Erythema Elevatum Diutinum. Dermatology, 2012, 224, 115-119.	0.9	9
87	Enoxaparin-Induced DRESS Syndrome. Case Reports in Dermatology, 2012, 4, 233-237.	0.3	20
89	Evaluation of polymorphisms in the sulfonamide detoxification genes NAT2, CYB5A, and CYB5R3 in patients with sulfonamide hypersensitivity. Pharmacogenetics and Genomics, 2012, 22, 733-740.	0.7	20
90	Allopurinolâ€induced drug rash with eosinophilia and systemic symptoms mimicking acute generalized exanthematous pustulosis. Journal of Dermatology, 2012, 39, 1077-1078.	0.6	9
91	Fatal Clindamycinâ€Induced <scp>D</scp> rug <scp>R</scp> ash with <scp>E</scp> osinophilia and <scp>S</scp> ymptoms (DRESS) Syndrome. Pharmacotherapy, 2012, 32, e387-92.	1.2	15
93	Raltegravir-induced DRESS syndrome. Scandinavian Journal of Infectious Diseases, 2012, 44, 802-803.	1.5	22
94	Human Herpesvirus 6 Reactivation in Drug-induced Hypersensitivity Syndrome and DRESS Validation Score. American Journal of Medicine, 2012, 125, e9-e10.	0.6	30
95	Severe cutaneous eruptions on telaprevir. Journal of Hepatology, 2012, 57, 470-472.	1.8	17

#	Article	IF	CITATIONS
96	Toxic epidermal necrolysis, DRESS, AGEP: Do overlap cases exist?. Orphanet Journal of Rare Diseases, 2012, 7, 72.	1.2	96
97	The association between DRESS and the diminished numbers of peripheral B lymphocytes and natural killer cells. Pediatric Allergy and Immunology, 2012, 23, 289-296.	1.1	15
98	Drug-Induced Hypersensitivity Syndrome: Recent Advances in the Diagnosis, Pathogenesis and Management. Chemical Immunology and Allergy, 2012, 97, 122-138.	1.7	54
99	Successful Treatment of Scleredema Diabeticorum by Combining Local PUVA and Colchicine: A Case Report. Case Reports in Dermatology, 2012, 4, 265-268.	0.3	13
100	Amikacin-induced drug reaction with eosinophilia and systemic symptoms syndrome: Delayed skin test and ELISPOT assay results allow the identification of the culprit drug. Journal of Allergy and Clinical Immunology, 2012, 130, 1413-1414.	1.5	37
101	A novel homozygous mutation in recombination activating gene 2 in 2 relatives with different clinical phenotypes: Omenn syndrome and hyper-IgM syndrome. Journal of Allergy and Clinical Immunology, 2012, 130, 1414-1416.	1.5	43
102	Cutaneous drug reactions. Journal of Allergy and Clinical Immunology, 2012, 130, 1225-1225.e6.	1.5	30
103	Drug Reaction with Eosinophilia and Systemic Symptoms: an update on pathogenesis. Current Opinion in Immunology, 2012, 24, 730-735.	2.4	64
104	Drug reaction with eosinophilia and systemic symptoms (DRESS) in a patient taking sitagliptin. Diabetes and Metabolism, 2012, 38, 571-573.	1.4	8
105	Successful treatment of exercise-induced anaphylaxis with omalizumab. Annals of Allergy, Asthma and Immunology, 2012, 109, 281-282.	0.5	35
106	Vancomycin-induced DRESS with evidence of T-cell activation in a 22-month-old patient. Annals of Allergy, Asthma and Immunology, 2012, 109, 280-281.	0.5	8
107	Drug reaction with Eosinophilia and Systemic Symptoms (DRESS) / Drug-induced Hypersensitivity Syndrome (DIHS): a review of current concepts. Anais Brasileiros De Dermatologia, 2012, 87, 435-449.	0.5	142
108	DRESS: clinicopathological features of 10 cases from an University Hospital in São Paulo. Anais Brasileiros De Dermatologia, 2012, 87, 703-707.	0.5	12
109	Cutaneous adverse drug reactions to allopurinol: 10 year observational survey of the dermatology department – Cagliari University (Italy). Journal of the European Academy of Dermatology and Venereology, 2012, 26, 1424-1430.	1.3	35
110	Prolonged elevation of serum granulysin in drug-induced hypersensitivity syndrome. British Journal of Dermatology, 2012, 167, 452-453.	1.4	26
111	Patch testing is an effective method for the diagnosis of carbamazepineâ€induced drug reaction, eosinophilia and systemic symptoms (DRESS) syndrome in an 8â€yearâ€old girl. Australasian Journal of Dermatology, 2012, 53, 274-277.	0.4	15
112	Fluindione and drug reaction with eosinophilia and systemic symptoms: an unrecognised adverse effect?. European Journal of Clinical Pharmacology, 2012, 68, 101-105.	0.8	9
113	A patch testing and crossâ€sensitivity study of carbamazepineâ€induced severe cutaneous adverse drug reactions. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 356-364.	1.3	55

#	Article	IF	CITATIONS
114	Clinical course of drugâ€induced hypersensitivity syndrome treated without systemic corticosteroids. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 722-726.	1.3	33
115	Drug reaction with eosinophilia and systemic symptoms syndrome in a patient taking phenytoin and levetiracetam: a case report. Journal of Medical Case Reports, 2013, 7, 2.	0.4	23
117	Drug rash with eosinophilia and systemic symptoms (DRESS) in patients receiving strontium ranelate. Osteoporosis International, 2013, 24, 1751-1757.	1.3	30
118	Phenytoin Induced DRESS Syndrome. Indian Journal of Pediatrics, 2013, 80, 266-266.	0.3	4
119	Atlas of Lymph Node Pathology. , 2013, , .		8
120	Lymphadenopathy Secondary to Drug-Induced Hypersensitivity Syndrome. , 2013, , 157-160.		0
121	Allopurinol Hypersensitivity: A Systematic Review of All Published Cases, 1950–2012. Drug Safety, 2013, 36, 953-980.	1.4	145
122	Antituberculosis drug-induced hypersensitivity syndrome and its association with human leukocyte antigen. Tuberculosis, 2013, 93, 270-274.	0.8	21
123	The role of viral infection in the development of severe drug eruptions. Dermatologica Sinica, 2013, 31, 205-210.	0.2	11
124	Drug reaction with eosinophilia and systemic symptoms (DRESS) induced by allopurinol: A case report. European Geriatric Medicine, 2013, 4, 99-101.	1.2	1
125	Systemic involvement of acute generalized exanthematous pustulosis: a retrospective study on 58 patients. British Journal of Dermatology, 2013, 169, 1223-1232.	1.4	121
127	Characteristics of liver injury in drug-induced systemic hypersensitivity reactions. Journal of the American Academy of Dermatology, 2013, 69, 407-415.	0.6	68
128	Reply to: "Using a diagnostic score when reporting the long-term sequelae of the drug reaction with eosinophilia and systemic symptoms― Journal of the American Academy of Dermatology, 2013, 69, 1060-1062.	0.6	13
129	Leflunomide-induced DRESS syndrome with renal involvement and vasculitis. Clinical Rheumatology, 2013, 32, 689-693.	1.0	18
130	Short- and long-term outcomes of 34 patients with drug-induced hypersensitivity syndrome in a single institution. Journal of the American Academy of Dermatology, 2013, 68, 721-728.	0.6	101
131	Long-term sequelae of drug reaction with eosinophilia and systemic symptoms: A retrospective cohort study from Taiwan. Journal of the American Academy of Dermatology, 2013, 68, 459-465.	0.6	145
132	Exanthema caused by ingestion of potassium <i>p</i> â€aminobenzoate (POTABAâ€Glenwood [®]). Contact Dermatitis, 2013, 68, 381-382.	0.8	1
133	Drug reaction with eosinophilia and systemic symptoms: A drug-induced hypersensitivity syndrome with variable clinical features. Dermatologica Sinica, 2013, 31, 196-204.	0.2	48

	Cr	TATION REPORT	
#	Article	IF	Citations
134	A Review of Cutaneous Drug Eruptions. Clinics in Geriatric Medicine, 2013, 29, 527-545.	1.0	22
135	Occupational trichloroethylene hypersensitivity syndrome: Human herpesvirus 6 reactivation and rash phenotypes. Journal of Dermatological Science, 2013, 72, 218-224.	1.0	32
136	Patch testing and sensitization to multiple drugs. Contact Dermatitis, 2013, 69, 296-302.	0.8	10
137	Optimal management of DRESS syndrome in course of infectious endocarditis. Annals of Allergy, Asthma and Immunology, 2013, 110, 303-305.	0.5	9
138	Using a diagnostic score when reporting the long-term sequelae of the drug reaction with eosinophilia and systemic symptoms syndrome. Journal of the American Academy of Dermatology, 20 69, 1059-1060.	13, 0.6	0
139	Pneumopathies interstitielles diffuses Actualités. Revue Des Maladies Respiratoires Actualites, 2013 63-69.	3, 5, 0.0	1
140	Cytokine gene expression profiling to help identify a safe antibiotic in a patient with drug rash with eosinophilia and systemic symptoms. Journal of Allergy and Clinical Immunology: in Practice, 2013, 1, 531-533.	2.0	3
141	Severe DRESS Syndrome Managed With Therapeutic Plasma Exchange. Pediatrics, 2013, 131, e945-e	949. 1.0	27
142	Drug reaction with eosinophilia and systemic symptoms: is cutaneous phenotype a prognostic marker for outcome? A review of clinicopathological features of 27 cases. British Journal of Dermatology, 2013, 168, 391-401.	r 1.4	97
143	DRESS syndrome. Journal of the American Academy of Dermatology, 2013, 68, 693.e1-693.e14.	0.6	332
144	Erythroderma in the emergency department. BMJ, The, 2013, 346, f3613-f3613.	3.0	1
145	Saliva Polymerase Chain Reaction Assay for Detection and Follow-up of Herpesvirus Reactivation in Patients With Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS). JAMA Dermatology, 2013, 149, 565.	, 2.0	22
146	Clinical Features and Prognostic Factors in Severe Cutaneous Drug Reactions. International Archives of Allergy and Immunology, 2013, 162, 346-354.	0.9	41
148	Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse dru reaction. Results from the prospective RegiSCAR study. British Journal of Dermatology, 2013, 169, 1071-1080.	lg 1.4	652
149	Association between HLA-B*1301 and Dapsone-Induced Hypersensitivity Reactions among Leprosy Patients in China. Journal of Investigative Dermatology, 2013, 133, 2642-2644.	0.3	46
150	Pregabalin hypersensitivity in a patient treated for postherpetic neuralgia. Indian Journal of Pharmacology, 2013, 45, 522.	0.4	15
151	Eosinophilia in pre-anesthetic assessment: A guide to diagnosis of DRESS syndrome. Journal of Anaesthesiology Clinical Pharmacology, 2013, 29, 270.	0.2	2
152	A rare case of ethambutol induced pulmonary eosinophilia. Journal of Pharmacology and Pharmacotherapeutics, 2013, 4, 300-302.	0.2	5

	CITATION	CITATION REPORT	
#	ARTICLE A Case of Drug Reaction with Eosinophilia and Systemic Symptoms Induced by Ethambutol with Early	IF	CITATIONS
153	Features Resembling Stevens-Johnson Syndrome. Acta Dermato-Venereologica, 2013, 93, 753-754.	0.6	13
154	Drug-Induced Hypersensitivity Syndrome Induced by Clindamycin. Acta Dermato-Venereologica, 2013, 93, 83-84.	0.6	11
155	Shock State. Shock, 2013, 40, 387-391.	1.0	16
156	A Case of Recalcitrant DRESS Syndrome With Multiple Autoimmune Sequelae Treated With Intravenous Immunoglobulins. JAMA Dermatology, 2013, 149, 494.	2.0	31
157	Facial Stigmata and Their Powerful Effects in Literature and Life. JAMA Dermatology, 2013, 149, 569.	2.0	0
158	Captopril-Induced DRESS. Dermatitis, 2013, 24, 255-257.	0.8	7
159	DRESS Syndrome due to Nevirapine Treated with Methylprednisolone. Case Reports in Medicine, 2013, 2013, 1-4.	0.3	8
160	Anesthetic management of difficult airway in a patient with massive neurofibroma of face: Utility of Rendell Baker Soucek mask and left molar approach for ventilation and intubation. Journal of Anaesthesiology Clinical Pharmacology, 2013, 29, 271.	0.2	9
161	A New Case of DRESS Syndrome Induced by Sulfasalazine and Triggered by Amoxicillin. Case Reports in Rheumatology, 2013, 2013, 1-3.	0.2	14
162	Successful Treatment of Antiepileptic Drug-Induced DRESS Syndrome with Pulse Methylprednisolone. Case Reports in Pediatrics, 2013, 2013, 1-4.	0.2	27
163	Thyroid dysfunction in drug reaction with eosinophilia and systemic symptoms (DRESS): an unusual manifestation of systemic drug hypersensitivity. British Journal of Dermatology, 2013, 168, 1130-1132.	1.4	17
164	Idiosyncratic Adverse Drug Reactions: Current Concepts. Pharmacological Reviews, 2013, 65, 779-808.	7.1	253
165	<i>HLA-B*58:01</i> is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis in a Portuguese population. British Journal of Dermatology, 2013, 169, 660-665.	1.4	107
166	Evidence for Reactivation of Human Herpesvirus 6 in Generalized Lymphadenopathy in a Patient with Drug-Induced Hypersensitivity Syndrome. Journal of Clinical Microbiology, 2013, 51, 1979-1982.	1.8	17
167	Raltegravir-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome – Implications for clinical practice and patient safety. International Journal of STD and AIDS, 2013, 24, 639-642.	0.5	25
168	Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome Associated With Antituberculosis Medications. Pediatric Infectious Disease Journal, 2013, 32, 1388-1390.	1.1	11
169	DRESS syndrome induced by acenocoumarol with tolerance to warfarin and dabigatran. Blood Coagulation and Fibrinolysis, 2013, 24, 576-578.	0.5	9
170	Eosinophils in Severe Sepsis in Northern Australia. Critical Care Medicine, 2013, 41, e286-e288.	0.4	8

#	Article	IF	CITATIONS
171	Pulmonary Nodules in an Immunocompetent Child With Cat Scratch Disease. Pediatric Infectious Disease Journal, 2013, 32, 1390-1392.	1.1	5
172	Nitrofurantoin: cause of DRESS syndrome. BMJ Case Reports, 2013, 2013, bcr2013008991-bcr2013008991.	0.2	12
174	A Case of Sulfasalazine-Induced Hypersensitivity Syndrome Confirmed by Enzyme-Linked Immunospot Assay. Allergy, Asthma and Immunology Research, 2013, 5, 415.	1.1	15
175	Dapsone-induced drug reaction with eosinophilia and systemic symptoms syndrome, misdiagnosed as lymphoma. Allergy Asthma & Respiratory Disease, 2013, 1, 400.	0.3	0
176	Relationships between serum vitamin D levels and clinical characteristics of drug reaction with eosinophilia and systemic symptoms syndrome. Allergy Asthma & Respiratory Disease, 2013, 1, 144.	0.3	1
177	Severe Cutaneous Adverse Reactions. , 0, , .		0
178	G46 Arrived safely? Audit of documentation of successful transfer into adult care of young people attending adolescent rheumatology clinics. Archives of Disease in Childhood, 2014, 99, A19-A20.	1.0	0
179	G49 Acne fulminans induced by oral isotretinoin. Archives of Disease in Childhood, 2014, 99, A20-A21.	1.0	0
180	Clinicopathologic Correlation of Oral Lichen Planus and Oral Lichenoid Lesions: A Preliminary Study. Scientific World Journal, The, 2014, 2014, 1-6.	0.8	34
182	Drug Reaction with Eosinophilia and Systemic Symptom (DRESS) induced by carbamazepine: a case report and literature review. Pan African Medical Journal, 2014, 18, 9.	0.3	34
183	Comparison of Diagnostic Criteria and Determination of Prognostic Factors for Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome. Allergy, Asthma and Immunology Research, 2014, 6, 216.	1.1	64
184	Severe Agranulocytosis in Two Patients with Drug-induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms. Acta Dermato-Venereologica, 2014, 96, 842-3.	0.6	4
185	Lamotrigine-induced toxic epidermal necrolysis confirmed by in vitro granulysin and cytokine assays. Asia Pacific Allergy, 2014, 4, 253-256.	0.6	6
186	Toxic epidermal necrolysis: a retrospective analysis of 17 cases from Central Tunisia. Pan African Medical Journal, 2014, 19, 269.	0.3	3
188	HLA and TCR Recognition of Medications in Severe Cutaneous Adverse Reactions. Current Immunology Reviews, 2014, 10, 51-61.	1.2	3
189	Cutaneous vasculitis overlap with acute generalised exanthematous pustulosis (AGEP). BMJ Case Reports, 2014, 2014, bcr2014206362-bcr2014206362.	0.2	3
190	Localised bullous eruptions and epidermal detachment from the extravasation of hydroxyethyl starch (Voluven). BMJ Case Reports, 2014, 2014, bcr2014207314-bcr2014207314.	0.2	2
191	Different Roads, Same Destination. Journal of Investigative Dermatology, 2014, 134, 1154-1155.	0.3	0

#	Article	IF	CITATIONS
192	Imatinib causing drug rash with eosinophilia and systemic symptoms: A rare cutaneous reaction. Indian Dermatology Online Journal, 2014, 5, 120.	0.2	8
193	General Aspects of Adverse Cutaneous Drug Reactions. , 2014, , 3-63.		2
194	Dermatologic adverse events of protease inhibitor-based combination therapy in patients with chronic hepatitis C. Journal of Dermatological Case Reports, 2014, 8, 95-102.	1.1	5
195	Cutaneous adverse drug reactions in Indian population: A systematic review. Indian Dermatology Online Journal, 2014, 5, 76.	0.2	63
196	Chronic Hepatitis C Therapy in Liver Cirrhosis Complicated by Telaprevir-Induced DRESS. Case Reports in Medicine, 2014, 2014, 1-6.	0.3	10
197	Reactivation of hepatitis B virus infection associated with maraviroc use in an HIV-infected patient. Aids, 2014, 28, 1079-1080.	1.0	1
198	Increased ratio of FoxP3+ regulatory T cells/CD3+ T cells in skin lesions in drug-induced hypersensitivity syndrome/drug rash with eosinophilia and systemic symptoms. Clinical and Experimental Dermatology, 2014, 39, 284-291.	0.6	27
199	Drug-reaction eosinophilia and systemic symptoms and drug-induced hypersensitivity syndrome. Australasian Journal of Dermatology, 2014, 55, 15-23.	0.4	43
200	Comparison of cytokine gene polymorphism in drugâ€induced maculopapular eruption, urticaria and drug reaction with eosinophilia and systemic symptoms (<scp>DRESS</scp>). Journal of the European Academy of Dermatology and Venereology, 2014, 28, 491-499.	1.3	21
201	Elevated serum thymus and activation-regulated chemokine (TARC/CCL17) relates to reactivation of human herpesvirus 6 in drug reaction with eosinophilia and systemic symptoms (DRESS)/drug-induced hypersensitivity syndrome (DIHS). British Journal of Dermatology, 2014, 171, 425-427.	1.4	43
202	Histopathological analysis and clinical correlation of drug reaction with eosinophilia and systemic symptoms (DRESS). British Journal of Dermatology, 2014, 170, 866-873.	1.4	52
203	Novel finding of carbamazepine induced gall bladder granulomatous vasculitis. Internal Medicine Journal, 2014, 44, 700-703.	0.5	6
204	Drug reaction with eosinophilia and systemic symptoms syndrome (DRESS) syndrome associated with azithromycin presenting like septic shock: a case report. Journal of Medical Case Reports, 2014, 8, 332.	0.4	22
205	Drug reaction with eosinophilia and systemic symptoms associated with raltegravir use. Aids, 2014, 28, 1077-1079.	1.0	11
206	Massive hypereosinophilia and vasculitis associated with major expansion of interleukin-5-producing CD8+ T cells in HIV-1 infection. Aids, 2014, 28, 1075-1077.	1.0	1
208	HHV-6A and HHV-6B in Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms. , 2014, , 179-200.		2
209	Stevens–Johnson Syndrome and toxic epidermalnecrolysis: a multi-aspect comparative 7-year study from the People's Republic of China. Drug Design, Development and Therapy, 2014, 8, 2539.	2.0	14
210	Genetic Variants Associated With Phenytoin-Related Severe Cutaneous Adverse Reactions. JAMA - Journal of the American Medical Association, 2014, 312, 525.	3.8	256

#	Article	IF	CITATIONS
211	Drug Reaction with Eosinophilia and Systemic Symptoms: DRESS following Initiation of Oxcarbazepine with Elevated Human Herpesvirus-6 Titer. Case Reports in Dermatological Medicine, 2014, 2014, 1-4.	0.1	4
212	DRESS syndrome as a complication of treatment of hepatitis C virus-associated post-inflammatory liver cirrhosis with peginterferon α2a and ribavirin. Postepy Dermatologii I Alergologii, 2014, 6, 401-404.	0.4	3
213	Drug reaction with eosinophilia and systemic symptoms syndrome caused by an everolimusâ€eluting stent. International Journal of Dermatology, 2014, 53, e286-8.	0.5	6
214	Genotype–phenotype association between HLA and carbamazepine-induced hypersensitivity reactions: Strength and clinical correlations. Journal of Dermatological Science, 2014, 73, 101-109.	1.0	76
216	DRESS syndrome. Joint Bone Spine, 2014, 81, 15-21.	0.8	94
218	Severe Cutaneous Adverse Reactions Related to Systemic Antibiotics. Clinical Infectious Diseases, 2014, 58, 1377-1385.	2.9	88
219	Drug reaction with eosinophilia and systemic symptoms, or virus reactivation with eosinophilia and systemic symptoms as a manifestation of immune reconstitution inflammatory syndrome in a patient with <scp>HIV</scp> ?. British Journal of Dermatology, 2014, 171, 895-898.	1.4	22
223	A unique case of bullous drug eruption related to vancomycin and cefoperazone. European Journal of Dermatology, 2014, 24, 378-379.	0.3	2
224	HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis. Pharmacogenomics Journal, 2014, 14, 281-288.	0.9	199
225	Evidence for human herpesvirus-6B infection of regulatory T-cells in acute systemic lymphadenitis in an immunocompetent adult with the drug reaction with eosinophilia and systemic symptoms syndrome: A case report. Journal of Clinical Virology, 2014, 61, 448-452.	1.6	20
226	Omeprazole-induced drug reaction with eosinophilia and systemic symptoms (DRESS). European Journal of Dermatology, 2014, 24, 413-415.	0.3	14
227	Comments on: DRESS syndrome. Journal of the American Academy of Dermatology, 2014, 71, 1000-1000.e2.	0.6	44
228	Management of Nonimmediate Hypersensitivity Reactions to Drugs. Immunology and Allergy Clinics of North America, 2014, 34, 473-487.	0.7	20
229	Severe flucloxacillin-induced acute generalized exanthematous pustulosis (AGEP), with toxic epidermal necrolysis (TEN)-like features: does overlap between AGEP and TEN exist? Clinical report and review of the literature. British Journal of Dermatology, 2014, 171, 1539-1545.	1.4	29
230	Clinical and laboratory improvement after intravenous immunoglobulin in drug reaction with eosinophilia and systemic symptoms. Journal of Allergy and Clinical Immunology: in Practice, 2014, 2, 107-110.	2.0	22
231	Severe enterocolitis associated with antiepileptic-induced drug reaction with eosinophilia and systemic symptoms. Human Pathology, 2014, 45, 1973-1977.	1.1	15
232	Suspected Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Secondary to Quetiapine in an Elderly Patient. International Journal of Gerontology, 2014, 8, 45.	0.7	6
233	Drug Allergy Diagnosis. Immunology and Allergy Clinics of North America, 2014, 34, 461-471.	0.7	11

#	Article	IF	CITATIONS
235	Fatal case of cephalexin-induced toxic epidermal necrolysis. SAGE Open Medical Case Reports, 2014, 2, 2050313X1453225.	0.2	2
237	A Suspected Case of Efavirenz-Induced Stevens–Johnson Syndrome. Drug Safety - Case Reports, 2015, 2, 15.	0.9	6
238	Severe drugâ€induced skin reactions: clinical features, diagnosis, etiology, and therapy. JDDG - Journal of the German Society of Dermatology, 2015, 13, 625-643.	0.4	62
239	Toxic epidermal necrolysis and hemophagocytic lymphohistiocytosis: a case report and literature review. Clinical Case Reports (discontinued), 2015, 3, 121-125.	0.2	7
240	Genotyping <i>HLAâ€B*5801</i> for Allopurinolâ€Induced Severe Cutaneous Adverse Reactions: An Accurate and Prompt Method. Clinical and Translational Science, 2015, 8, 834-836.	1.5	5
241	Clinical characteristics and treatment outcome of Stevens-Johnson syndrome and toxic epidermal necrolysis. Experimental and Therapeutic Medicine, 2015, 10, 519-524.	0.8	28
242	DRESS Syndrome Following Levofloxacin Exposure With Positive Patch-test. Therapie, 2015, 70, 547-549.	0.6	13
243	Association of CD8+ T lymphocyte repertoire spreading with the severity of DRESS syndrome. Scientific Reports, 2015, 5, 9913.	1.6	27
244	Life Threatening, Allopurinol-related Dress Syndrome as a Rare Cause of Fever of Unknown Origin. Internal Medicine, 2015, 54, 2073-2077.	0.3	1
245	Drug-induced Liver Injury with Serious Multiform Exudative Erythema following the Use of an Over-the-counter Medication Containing Ibuprofen. Internal Medicine, 2015, 54, 395-399.	0.3	6
246	Lamotrigine Associated DRESS Syndrome – a Case Report. Serbian Journal of Dermatology and Venereology, 2015, 7, 23-33.	0.2	2
247	Toxic epidermal necrolysis related to AP (pemetrexed plus cisplatin) and gefitinib combination therapy in a patient with metastatic non-small cell lung cancer. Chinese Journal of Cancer, 2015, 34, 94-98.	4.9	30
248	Acute generalized exanthematous pustulosis induced by mifepristone. JAAD Case Reports, 2015, 1, 191-195.	0.4	5
249	Drug-induced hypersensitivity syndrome by liposomal amphotericin-B: a case report. BMC Research Notes, 2015, 8, 510.	0.6	8
250	Vancomycin-induced acute generalized exanthematous pustulosis (AGEP) masquerading septic shock—an unusual presentation of a rare disease. Journal of Intensive Care, 2015, 3, 47.	1.3	16
251	Drug reaction with eosinophilia and systemic symptoms (DRESS): clinicopathological study of 45 cases. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 2199-2205.	1.3	42
252	Febuxostat-associated drug reaction with eosinophilia and systemic symptoms (DRESS). Journal of Clinical Pharmacy and Therapeutics, 2015, 40, 689-692.	0.7	27
253	Human herpes virus reactivations and dynamic cytokine profiles in patients with cutaneous adverse drug reactions– a prospective comparative study. Allergy: European Journal of Allergy and Clinical Immunology, 2015, 70, 568-575.	2.7	49

#	Article	IF	CITATIONS
254	<i> <scp>HLA</scp> ―<scp>B</scp> *58:01 </i> is strongly associated with allopurinolâ€induced severe cutaneous adverse reactions in <scp>H</scp> an <scp>C</scp> hinese patients: a multicentre retrospective case–control clinical study. British Journal of Dermatology, 2015, 173, 555-558.	1.4	48
255	Sequelae in 145 patients with drugâ€induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms: Survey conducted by the Asian Research Committee on Severe Cutaneous Adverse Reactions (<scp>ASCAR</scp>). Journal of Dermatology, 2015, 42, 276-282.	0.6	97
256	Histopathology of drug rash with eosinophilia and systemic symptoms syndrome: a morphological and phenotypical study. British Journal of Dermatology, 2015, 173, 50-58.	1.4	104
257	Drug reaction with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome: clinical features of 27 patients. Clinical and Experimental Dermatology, 2015, 40, 851-859.	0.6	48
258	Author reply. Internal Medicine Journal, 2015, 45, 234-235.	0.5	0
259	Addressing DRESS (drug reaction with eosinophilia and systemic symptoms). Adverse Drug Reaction Bulletin, 2015, 295, 1139-1142.	0.6	3
260	Successful Treatment of Hydroxychloroquine-Induced Recalcitrant Acute Generalized Exanthematous Pustulosis with Cyclosporine: Case Report and Literature Review. Annals of Dermatology, 2015, 27, 431.	0.3	16
261	A case of acute generalized exanthematous pustulosis associated with polyarteritis nodosa, responding to systemic steroids. Journal of Community Hospital Internal Medicine Perspectives, 2015, 5, 26645.	0.4	3
262	Phenytoin Induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). Journal of Nepal Paediatric Society, 2015, 35, 73-75.	0.1	3
263	Drug-induced skin reactions: a 2-year study. Clinical, Cosmetic and Investigational Dermatology, 2015, 8, 53.	0.8	11
265	Stevens Johnson Syndrome and Toxic Epidermal Necrolysis: Maternal and Foetal Outcomes in Twenty-Two Consecutive Pregnant HIV Infected Women. PLoS ONE, 2015, 10, e0135501.	1.1	13
266	Toxic Epidermal Necrolysis in Polymedicated Patient Treated With Radiotherapy. Allergy, Asthma and Immunology Research, 2015, 7, 199.	1.1	1
267	HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in Vietnamese. Asia Pacific Allergy, 2015, 5, 68-77.	0.6	89
268	Five-Year Retrospective Review of Acute Generalized Exanthematous Pustulosis. Dermatology Research and Practice, 2015, 2015, 1-8.	0.3	29
269	An Uncommon Side Effect of Bupropion: A Case of Acute Generalized Exanthematous Pustulosis. Case Reports in Dermatological Medicine, 2015, 2015, 1-3.	0.1	3
270	Drug Reaction, Eosinophilia and Systemic Symptoms (DRESS) syndrome secondary to allopurinol with early lymphadenopathy and symptom relapse. BMJ Case Reports, 2015, 2015, bcr2015211222.	0.2	5
271	Two cases with HSS/DRESS syndrome developing after prosthetic joint surgery: does vancomycin-laden bone cement play a role in this syndrome?. BMJ Case Reports, 2015, 2015, bcr2014207028-bcr2014207028.	0.2	16
272	Toxic epidermal necrolysis with the use of tamoxifen. BMJ Case Reports, 2015, 2015, bcr2014209102-bcr2014209102.	0.2	7

#	Article	IF	CITATIONS
273	Lamotrigine-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). BMJ Case Reports, 2015, 2015, bcr2014209170-bcr2014209170.	0.2	3
274	Association analysis of CYP2C9*3 and phenytoin-induced severe cutaneous adverse reactions (SCARs) in Thai epilepsy children. Journal of Human Genetics, 2015, 60, 413-417.	1.1	28
275	A case of acute interstitial nephritis and granulomatous hepatitis induced by ingesting quinine. CEN Case Reports, 2015, 4, 76-80.	0.5	2
276	DRESS syndrome induit par la téicoplanine. Revue Francaise D'allergologie, 2015, 55, 308-311.	0.1	2
278	Peripheral blood eosinophilia and hypersensitivity reactions among patients receiving outpatient parenteral antibiotics. Journal of Allergy and Clinical Immunology, 2015, 136, 1288-1294.e1.	1.5	36
279	Recent advances of pharmacogenomics in severe cutaneous adverse reactions: immune and nonimmune mechanisms. Asia Pacific Allergy, 2015, 5, 59-67.	0.6	23
280	Autoimmune blistering diseases in females: a review. International Journal of Women's Dermatology, 2015, 1, 4-12.	1.1	29
281	Schwere arzneimittelinduzierte Hautreaktionen: Klinik, Diagnostik, Ätiologie und Therapie. JDDG - Journal of the German Society of Dermatology, 2015, 13, 625-645.	0.4	39
282	Acute generalized exanthematous pustulosis associated with primary Epstein-Barr virus infection. JAAD Case Reports, 2015, 1, 9-11.	0.4	12
283	Severe DRESS syndrome secondary to sulfamethoxazole/trimethoprim complicated by hyperthyroidism, photosensitivity, anhidrosis, and juvenile idiopathic arthritis. Dermatologica Sinica, 2015, 33, 33-34.	0.2	1
284	Therapeutic management of DRESS: A retrospective study of 38 cases. Journal of the American Academy of Dermatology, 2015, 72, 246-252.	0.6	110
285	A 2½-Year-Old Girl With a Diffuse Erythematous Rash and Fever. Clinical Pediatrics, 2015, 54, 1299-1301.	0.4	0
286	A case report on toxic epidermal necrolysis with etoricoxib. Indian Journal of Pharmacology, 2015, 47, 221.	0.4	12
287	HLA-B allele and haplotype diversity among Thai patients identified by PCR-SSOP: evidence for high risk of drug-induced hypersensitivity. Frontiers in Genetics, 2014, 5, 478.	1.1	31
288	Lamotrigine induced DIHS/DRESS: Manifestations, treatment, and outcome in 57 patients. Clinical Neurology and Neurosurgery, 2015, 138, 1-7.	0.6	19
289	A rare case of DRESS syndrome caused by vancomycin. Journal of Acute Medicine, 2015, 5, 74-76.	0.2	3
290	RIPping the Skin Apart: Necroptosis Signaling in Toxic Epidermal Necrolysis. Journal of Investigative Dermatology, 2015, 135, 1940-1943.	0.3	11
291	DRESS syndrome: cerebral vasculitic-like presentation. Neuroradiology, 2015, 57, 1015-1021.	1.1	11

ARTICLE IF CITATIONS Report from the National Institute of Allergy and Infectious Diseases workshop on drug allergy. 292 1.5 51 Journal of Allergy and Clinical Immunology, 2015, 136, 262-271.e2. A retrospective study of cutaneous drug reactions in an outpatient population. International Journal 1.0 of Clinical Pharmacy, 2015, 37, 739-743. Spectrum of Eosinophilic End-Organ Manifestations. Immunology and Allergy Clinics of North 295 0.7 53 America, 2015, 35, 403-411. DIHS/DRESS with Remarkable Eosinophilic Pneumonia Caused by Zonisamide. Acta 296 Dermato-Venereologica, 2015, 95, 229-230. A Pharmacogenetics Study in Mozambican Patients Treated with Nevirapine: Full Resequencing of 297 TRAF3IP2 Gene Shows a Novel Association with SJS/TEN Susceptibility. International Journal of 7 1.8 Molecular Sciences, 2015, 16, 5830-5838. Liver injury in patients with DRESS: A clinical study of 72 cases. Journal of the American Academy of Dermatology, 2015, 72, 984-991. 298 0.6 59 Human herpesvirus 6 involvement in paediatric drug hypersensitivity syndrome. British Journal of 299 1.4 5 Dermatology, 2015, 172, 858-859. Erythema multiforme-like drug reaction with eosinophilia and systemic symptoms (DRESS). Clinical 300 0.6 and Experimental Dermatology, 2015, 40, 455-456. Stevens-Johnson syndrome and toxic epidermal necrolysis: A cross-sectional analysis of patients in an 301 integrated allergy repository of a large health care system. Journal of Allergy and Clinical 2.0 28 Immunology: in Practice, 2015, 3, 277-280.e1. Acute generalized exanthematous pustulosis following paracetamol ingestion in a child. Pediatric 1.1 Allergy and Immunology, 2015, 26, 391-392. Dress induced by piperacillin-tazobactam in a child. Journal of Allergy and Clinical Immunology: in 303 2.0 5 Practice, 2015, 3, 615-617. Drug Hypersensitivity Reactions., 2015, , 219-231. 304 Fanconi Syndrome Induced by Vemurafenib. JAMA Dermatology, 2015, 151, 453. 305 2.0 14 Oxypurinol-Specific T Cells Possess Preferential TCR Clonotypes and Express Granulysin in Allopurinol-Induced Severe Cutaneous Adverse Reactions. Journal of Investigative Dermatology, 2015, 306 0.3 104 135, 2237-2248. 307 PharmGKB summary. Pharmacogenetics and Genomics, 2015, 25, 205-221. 19 0.7 Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study. 308 646 Gastroenterology, 2015, 148, 1340-1352.e7. Upregulated RIP3 Expression Potentiates MLKL Phosphorylation–Mediated Programmed Necrosis in 309 0.3 63 Toxic Epidermal Necrolysis. Journal of Investigative Dermatology, 2015, 135, 2021-2030. Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome Probably Induced by a 1.2 Lamotrigine-Ginseng Drug Interaction. Pharmacotherapy, 2015, 35, e9-e12.

#	Article	IF	CITATIONS
312	Post-traumatic stress disorder following drug reaction with eosinophilia and systemic symptoms. British Journal of Dermatology, 2015, 172, 836-837.	1.4	16
313	Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study. BMJ, The, 2015, 351, h4848.	3.0	148
314	Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): AÂNational Analysis of Data from 10-Year Post-marketing Surveillance. Drug Safety, 2015, 38, 1211-1218.	1.4	12
316	Recurrence of drugâ€induced reactions in <scp>DRESS</scp> patients. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 801-804.	1.3	55
317	Drug reaction with eosinophilia and systemic symptoms syndrome is not uncommon and shows better clinical outcome than generally recognised. Allergologia Et Immunopathologia, 2015, 43, 19-24.	1.0	15
318	DRESS syndrome induced by meropenem. Allergologia Et Immunopathologia, 2015, 43, 233-235.	1.0	13
319	Drug reaction with eosinophilia and systemic symptoms: manifestations, treatment, and outcome in 17 patients. International Journal of Dermatology, 2015, 54, 537-542.	0.5	32
320	Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin. Annals of the Rheumatic Diseases, 2015, 74, 2157-2164.	0.5	160
322	Human herpesvirus 6 involvement in paediatric drug hypersensitivity syndrome. British Journal of Dermatology, 2015, 172, 1090-1095.	1.4	37
323	Carbamazepine induced Stevens-Johnson syndrome. BMJ Case Reports, 2016, 2016, bcr2016214926.	0.2	5
324	Case of Steven-Johnson Syndrome in a male with breast cancer secondary to docetaxel/cyclophosphamide therapy. BMJ Case Reports, 2016, 2016, bcr2016217255.	0.2	5
325	A Unique Case of Angioedema With Anti-C1 Inhibitor Antibodies and Normal C1 Inhibitor Levels. Journal of Investigational Allergology and Clinical Immunology, 2016, 26, 111-112.	0.6	6
326	Toxic epidermal necrolysis. F1000Research, 2016, 5, 951.	0.8	19
327	Acute generalized exanthematous pustulosis associated with spider bite. Anais Brasileiros De Dermatologia, 2016, 91, 524-527.	0.5	11
328	DRESS Syndrome Caused by Cross-reactivity Between Vancomycin and Subsequent Teicoplanin Administration: A Case Report. American Journal of Case Reports, 2016, 17, 625-631.	0.3	21
329	Pharmacogenetics of antiepileptic drugs: A brief review. Mental Health Clinician, 2016, 6, 28-34.	0.5	6
330	A Case of Sorafenib-induced DRESS Syndrome in Hepatocelluar Carcinoma. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2016, 67, 337.	0.2	12
331	A Systemic Review on Staphylococcal Scalded Skin Syndrome (SSSS): A Rare and Critical Disease of Neonates. Open Microbiology Journal, 2016, 10, 150-159.	0.2	55

#	Article	IF	CITATIONS
332	DRESS Syndrome in the ICU: When a Patient Is Treated with Multiple Drugs. Case Reports in Critical Care, 2016, 2016, 1-4.	0.2	3
333	Intravenous Immunoglobulins: Mode of Action and Indications in Autoimmune and Inflammatory Dermatoses. International Journal of Inflammation, 2016, 2016, 1-6.	0.9	24
334	Toxic epidermal necrolysis and concurrent granulomatosis with polyangiitis (Wegener's) Tj ETQq0 0 0 rgBT / 2, 205951311664212.	Overlock 0.6	10 Tf 50 667 0
336	Rapid-onset of severe tigecycline-induced coagulopathy in drug reaction with eosinophilia and systemic symptom syndrome. Allergy Asthma & Respiratory Disease, 2016, 4, 74.	0.3	1
337	Acute Generalized Exanthematous Pustulosis: Pathogenesis, Genetic Background, Clinical Variants and Therapy. International Journal of Molecular Sciences, 2016, 17, 1214.	1.8	131
338	HLA Allele Frequencies in 5802 Koreans: Varied Allele Types Associated with SJS/TEN According to Culprit Drugs. Yonsei Medical Journal, 2016, 57, 118.	0.9	51
339	Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis Associated with Acetaminophen Use during Viral Infections. Immune Network, 2016, 16, 256.	1.6	18
340	The Importance of Patient-Specific Factors for Hepatic Drug Response and Toxicity. International Journal of Molecular Sciences, 2016, 17, 1714.	1.8	73
341	Severe Cutaneous Adverse Reactions: The Pharmacogenomics from Research to Clinical Implementation. International Journal of Molecular Sciences, 2016, 17, 1890.	1.8	39
342	Incidence of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Nationwide Population-Based Study Using National Health Insurance Database in Korea. PLoS ONE, 2016, 11, e0165933.	1.1	89
343	Review of Toxic Epidermal Necrolysis. International Journal of Molecular Sciences, 2016, 17, 2135.	1.8	43
344	Immunohistochemical Comparison of IL-36 and the IL-23/Th17 Axis of Generalized Pustular Psoriasis and Acute Generalized Exanthematous Pustulosis. Annals of Dermatology, 2016, 28, 451.	0.3	35
345	Atypical DRESS Syndrome Induced by Lenalidomide in Chronic Hemodialysis. , 2016, 6, .		0
346	Evaluation of the patients diagnosed with Stevens Johnson syndrome and toxic epidermal necrolysis: a single center experience. Turk Pediatri Arsivi, 2016, 51, 152-158.	0.9	6
347	Drug Reaction with Eosinophilia and Systemic Symptoms in Children: AÂProspective Study. Pediatric Dermatology, 2016, 33, e162-5.	0.5	29
348	Coâ€existence of histopathological features is characteristic in drug reaction with eosinophilia and systemic symptoms and correlates with high grades of cutaneous abnormalities. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 2077-2084.	1.3	17
349	Progression of drug exanthemas to serious drug eruptions: A retrospective review identifying early determinants. Australasian Journal of Dermatology, 2016, 57, e83-7.	0.4	4
350	Drug reaction with eosinophilia and systemic symptoms: a clinicopathological study of six cases at a teaching hospital in midwestern Brazil. International Journal of Dermatology, 2016, 55, 328-334.	0.5	5

#	Article	IF	CITATIONS
351	Overlap between maculopapular exanthema and drug reaction with eosinophilia and systemic symptoms among cutaneous adverse drug reactions in a dermatology ward. British Journal of Dermatology, 2016, 175, 1274-1283.	1.4	24
353	Cefotaxime-induced drug rash with eosinophilia and systemic symptoms syndrome in a 7-year-old boy. Annals of Allergy, Asthma and Immunology, 2016, 117, 202-204.	0.5	7
354	Associations between HLA class I and cytochrome P450 2C9 genetic polymorphisms and phenytoin-related severe cutaneous adverse reactions in a Thai population. Pharmacogenetics and Genomics, 2016, 26, 225-234.	0.7	94
355	Vitiligo: a potential autoimmune sequela of DRESS syndrome. British Journal of Dermatology, 2016, 175, 642-644.	1.4	4
356	Safety profile of etifoxine: A French pharmacovigilance survey. Fundamental and Clinical Pharmacology, 2016, 30, 147-152.	1.0	16
357	<scp>DRESS</scp> syndrome developed related to acetylsalicylic acid use. Pediatric Allergy and Immunology, 2016, 27, 227-230.	1.1	5
358	Autoimmune Limbic Encephalitis and Syndrome of Inappropriate Antidiuretic Hormone Secretion Associated with Lamotrigine-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) Syndrome. Internal Medicine, 2016, 55, 1393-1396.	0.3	15
359	Reactivation of Human Herpes Virus-6 in the Renal Tissue of a Patient with Drug-induced Hypersensitivity Syndrome/Drug Rash with Eosinophilia and Systemic Symptoms (DIHS/DRESS). Internal Medicine, 2016, 55, 1769-1774.	0.3	15
360	Multiple drug intolerance syndrome in an epileptic woman. Therapie, 2016, , .	0.6	0
361	Correspondence. Indian Pediatrics, 2016, 53, 745-752.	0.2	8
362	Is DRESS syndrome a single entity or within a spectrum of adverse reactions to drug?. British Journal of Dermatology, 2016, 175, 1142-1144.	1.4	4
363	Drug reaction with eosinophilia and systemic symptoms (DRESS): incidence, pathogenesis and management. Expert Opinion on Drug Safety, 2017, 16, 1-9.	1.0	68
364	Stevens–Johnson syndrome/toxic epidermal necrolysis caused by cefadroxil in a cat. Journal of Feline Medicine and Surgery Open Reports, 2016, 2, 205511691665361.	0.1	0
365	Impact of the HLA-B58:01 Allele and Renal Impairment on Allopurinol-Induced Cutaneous Adverse Reactions. Journal of Investigative Dermatology, 2016, 136, 1373-1381.	0.3	75
366	Peripheral blood mononuclear cell gene expression testing and the heterogeneity of T-cell–mediated drug reaction with eosinophilia and systemic symptoms syndrome. Annals of Allergy, Asthma and Immunology, 2016, 116, 584-585.	0.5	1
367	The Case of the Previously Shaky, Unimmunized, Itchy Infant With Rash and Pancytopenia. Clinical Pediatrics, 2016, 55, 1366-1368.	0.4	1
368	A fatal case of DRESS induced by strontium ranelate associated with HHV-7 reactivation. Osteoporosis International, 2016, 27, 1261-1264.	1.3	13
369	Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus. Lupus, 2016, 25, 1420-1430.	0.8	49

#	Article	IF	CITATIONS
370	Racial disparities in the risk of Stevens–Johnson Syndrome and toxic epidermal necrolysis as urate-lowering drug adverse events in the United States. Seminars in Arthritis and Rheumatism, 2016, 46, 253-258.	1.6	43
371	Psoriatic arthritis and psoriasis: differential diagnosis. Clinical Rheumatology, 2016, 35, 1893-1901.	1.0	64
372	Acute Hepatitis in the DRESS Syndrome. GE Portuguese Journal of Gastroenterology, 2016, 23, 304-308.	0.3	5
374	Systemic hypersensitivity reaction to Omnipaque radiocontrast medium: a case of miniâ€∢scp>DRESS. Clinical Case Reports (discontinued), 2016, 4, 336-338.	0.2	10
375	Approach to food allergy diagnosis and management by nonspecialty practitioners. Annals of Allergy, Asthma and Immunology, 2016, 116, 585-588.	0.5	2
376	Comparative histological analysis of drugâ€induced maculopapular exanthema and <scp>DRESS</scp> . Journal of the European Academy of Dermatology and Venereology, 2016, 30, 2085-2090.	1.3	17
377	Adult hemophagocytic lymphohistiocytosis causing multi organ dysfunction in a patient with multiple autoimmune disorders: when the immune system runs amok. Clinical Case Reports (discontinued), 2016, 4, 165-170.	0.2	8
378	Dermatological sideâ€effects in hepatitis C infected patients under a triple regimen associating pegylated interferon, ribavirin and telaprevir. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 143-146.	1.3	5
379	Association of <scp>HLA</scp> genotypes with phenobarbital hypersensitivity in children. Epilepsia, 2016, 57, 1610-1616.	2.6	28
380	Drug induced exfoliative dermatitis: state of the art. Clinical and Molecular Allergy, 2016, 14, 9.	0.8	14
381	A multiplex alleleâ€specific realâ€time polymerase chain reaction assay for <i>HLAâ€B*13:01</i> genotyping in four Chinese populations. Hla, 2016, 88, 164-171.	0.4	10
382	HLA and Delayed Drug-Induced Hypersensitivity. International Archives of Allergy and Immunology, 2016, 170, 163-179.	0.9	35
383	Das Dokumentationszentrum schwerer Hautreaktionen. , 2016, , 403-416.		1
384	Griseofulvin associated with drug reaction with eosinophilia and systemic symptoms (DRESS). JAAD Case Reports, 2016, 2, 315-316.	0.4	5
385	Histopathological study of six types of adverse cutaneous drug reactions using granulysin expression. International Journal of Dermatology, 2016, 55, 1225-1233.	0.5	27
386	SÃndrome DRESS. EMC - DermatologÃa, 2016, 50, 1-9.	0.1	0
388	Deadly Dermatologic Diseases. , 2016, , .		2
389	Drug Reaction with Eosinophilia and Systemic Symptoms. , 2016, , 169-171.		0

	Сітатіс	CITATION REPORT	
#	Article	IF	Citations
390	Pyrexia of unknown origin associated with rosuvastatin. Internal Medicine Journal, 2016, 46, 1225-1226.	0.5	1
391	Relapsing drug-induced hypersensitivity syndrome. Current Opinion in Allergy and Clinical Immunology, 2016, 16, 333-338.	1.1	9
392	Old dog begging for new tricks: current practices and future directions in the diagnosis of delayed antimicrobial hypersensitivity. Current Opinion in Infectious Diseases, 2016, 29, 561-576.	1.3	15
393	Pompholyx as a clinical manifestation suggesting increased serum IgG levels in a patient with drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. British Journal of Dermatology, 2016, 174, 681-683.	1.4	4
394	Two cases of overlap severe cutaneous adverse reactions to benznidazole treatment for asymptomatic Chagas disease in a nonendemic country. British Journal of Dermatology, 2016, 175, 604-607.	1.4	18
395	Risk assessment of drug-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a disproportionality analysis using the French Pharmacovigilance Database. British Journal of Dermatology, 2016, 175, 1067-1069.	1.4	13
396	<i>In vitro</i> test to confirm diagnosis of allopurinol-induced severe cutaneous adverse reactions. British Journal of Dermatology, 2016, 175, 994-1002.	1.4	27
397	What is This Rash?. Journal of Medical Toxicology, 2016, 12, 199-200.	0.8	2
399	Histopathology of the Exanthema in DRESS Is Not Specific but May Indicate Severity of Systemic Involvement. American Journal of Dermatopathology, 2016, 38, 423-433.	0.3	19
400	The Role and Immunobiology of Eosinophils in the Respiratory System: a Comprehensive Review. Clinical Reviews in Allergy and Immunology, 2016, 50, 140-158.	2.9	42
401	Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome Induced by Levetiracetam in a Pediatric Patient. Journal of Emergency Medicine, 2016, 50, e61-e66.	0.3	12
402	Adverse cutaneous drug eruptions: current understanding. Seminars in Immunopathology, 2016, 38, 75-86.	2.8	112
403	Use of the Biopharmaceutics Drug Disposition Classification System (BDDCS) to Help Predict the Occurrence of Idiosyncratic Cutaneous Adverse Drug Reactions Associated with Antiepileptic Drug Usage. AAPS Journal, 2016, 18, 757-766.	2.2	14
404	Severe cutaneous adverse reaction associated with vemurafenib: <scp>DRESS</scp> , <scp> AGEP</scp> or overlap reaction?. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 178-179.	1.3	29
405	Severe adverse drug reactions. Clinical Medicine, 2016, 16, 79-83.	0.8	16
406	Hypersensitivity Reactions, Dietary Supplements, andÂtheÂImportance of the Case Report. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 177-178.	2.0	1
407	The 9th International Congress on Cutaneous Adverse Drug Reactions at the 23rd World Congress of Dermatology in Vancouver, 2015. Drug Safety, 2016, 39, 271-276.	1.4	3
408	Cutaneous Adverse Effects of Neurologic Medications. CNS Drugs, 2016, 30, 245-267.	2.7	4

#	Article	IF	CITATIONS
409	Toxic epidermal necrolysis associated with radiotherapy and phenytoin in a patient with non-Hodking's lymphoma: A case report. Reports of Practical Oncology and Radiotherapy, 2016, 21, 81-83.	0.3	2
410	Adverse drug reactions and organ damage: The skin. European Journal of Internal Medicine, 2016, 28, 17-24.	1.0	57
411	Toxic epidermal necrolysis due to therapy with cyclophosphamide and mesna. Zeitschrift Fur Rheumatologie, 2016, 75, 200-202.	0.5	6
412	Drug rash with eosinophilia and systemic symptoms caused by the dietary supplement diindolylmethane. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 175-176.	2.0	5
413	Allopurinol hypersensitivity: investigating the cause and minimizing the risk. Nature Reviews Rheumatology, 2016, 12, 235-242.	3.5	139
414	Severe delayed skin reactions related to drugs in the paediatric age group: A review of the subject by way of three cases (Stevens–Johnson syndrome, toxic epidermal necrolysis and DRESS). Allergologia Et Immunopathologia, 2016, 44, 83-95.	1.0	21
415	Association of HLA-B*15:13 and HLA-B*15:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population. Pharmacogenomics Journal, 2017, 17, 170-173.	0.9	81
416	Leucoaféresis en el tratamiento del sÃndrome de drug rash with eosinophilia and systemic symptoms. Medicina Intensiva, 2017, 41, 191-193.	0.4	3
417	DRESS Syndrome or Hematologic Malignancy?. Pediatric Emergency Care, 2017, 33, 494-496.	0.5	10
418	Drug reaction with eosinophilia and systemic symptoms (DRESS) induced by imatinib in chronic myeloid leukemia. Leukemia and Lymphoma, 2017, 58, 473-474.	0.6	8
419	Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) with Teicoplanin: A Case Report. Drug Safety - Case Reports, 2017, 4, 1.	0.9	11
420	Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome and the Rheumatologist. Current Rheumatology Reports, 2017, 19, 3.	2.1	21
423	Spared white islands in a drug rash: revisiting sparing phenomenon in Hansen's disease. International Journal of Dermatology, 2017, 56, e102-e104.	0.5	3
424	An exploratory factor analysis of the spontaneous reporting of severe cutaneous adverse reactions. Therapeutic Advances in Drug Safety, 2017, 8, 4-16.	1.0	22
425	Recent advances in the understanding of severe cutaneous adverse reactions. British Journal of Dermatology, 2017, 177, 1234-1247.	1.4	27
426	Association of the HLA-B*53:01 Allele With Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome During Treatment of HIV Infection With Raltegravir. Clinical Infectious Diseases, 2017, 64, 1198-1203.	2.9	27
427	Candidate Gene Association Studies of Anthracycline-induced Cardiotoxicity: A Systematic Review and Meta-analysis. Scientific Reports, 2017, 7, 39.	1.6	80
428	Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Associations, Outcomes, and Pathobiology—Thirty Years of Progress but Still Much to Be Done. Journal of Investigative Dermatology, 2017, 137, 1004-1008.	0.3	66

#	ARTICLE	IF	CITATIONS
429	Influence of genetic and non-genetic factors on phenytoin-induced severe cutaneous adverse drug reactions. European Journal of Clinical Pharmacology, 2017, 73, 855-865.	0.8	58
430	Severe cutaneous adverse reactions to drugs. Lancet, The, 2017, 390, 1996-2011.	6.3	293
431	Severe Delayed Cutaneous and Systemic Reactions to Drugs: A Global Perspective on the Science and Art of Current Practice. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 547-563.	2.0	106
432	HLA-B*15:21 and carbamazepine-induced Stevens-Johnson syndrome: pooled-data and in silico analysis. Scientific Reports, 2017, 7, 45553.	1.6	46
433	Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Concise Review with a Comprehensive Summary of Therapeutic Interventions Emphasizing Supportive Measures. Advances in Therapy, 2017, 34, 1235-1244.	1.3	131
435	HLA B62 as a possible risk factor for drug reaction with eosinophilia and systemic symptoms to piperacillin/tazobactam. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 829-830.	2.0	14
436	Acute Liver Failure/Injury Related to Drug Reaction With Eosinophilia and Systemic Symptoms. Transplantation, 2017, 101, 1830-1837.	0.5	32
437	Risk factors of allopurinol-induced severe cutaneous adverse reactions in a Thai population. Pharmacogenetics and Genomics, 2017, 27, 255-263.	0.7	25
438	DRESS syndrome: Addressing the drug hypersensitivity syndrome on combination of Sodium Valproate and Olanzapine. Asian Journal of Psychiatry, 2017, 28, 175-176.	0.9	13
439	Management of Toxic Epidermal Necrolysis with Plasmapheresis and Cyclosporine A. Plastic and Reconstructive Surgery - Global Open, 2017, 5, e1221.	0.3	18
440	Protective role of α-lipoic acid in hyperuricemia-induced endothelial dysfunction. Experimental and Therapeutic Medicine, 2017, 13, 3047-3054.	0.8	21
441	Gout: An old disease in new perspective – A review. Journal of Advanced Research, 2017, 8, 495-511.	4.4	329
442	Clozapine-induced DRESS syndrome with multiple and rare organ involvement. Asian Journal of Psychiatry, 2017, 28, 146-147.	0.9	13
443	Exacerbation of allopurinol-induced drug reaction with eosinophilia and systemic symptoms by teicoplanin: A case report. Journal of Clinical Pharmacy and Therapeutics, 2017, 42, 642-645.	0.7	4
444	Approach to Severe Cutaneous Adverse Drug Reactions. Current Treatment Options in Allergy, 2017, 4, 201-221.	0.9	2
445	Systemic Immunomodulating Therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. JAMA Dermatology, 2017, 153, 514.	2.0	235
446	Approach to the diagnosis of drug hypersensitivity reactions: similarities and differences between Europe and North America. Clinical and Translational Allergy, 2017, 7, 7.	1.4	79
447	Is universal <i>HLA-B*15:02</i> screening a cost-effective option in an ethnically diverse population? A case study of Malaysia. British Journal of Dermatology, 2017, 177, 1102-1112.	1.4	18

#	Article	IF	CITATIONS
448	Severe Cutaneous Adverse Drug Reactions in Pediatric Patients: A Multicenter Study. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 757-763.	2.0	64
449	Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States. Journal of the American Academy of Dermatology, 2017, 76, 811-817.e4.	0.6	83
450	Cutaneous adverse drug reaction referrals to a liaison dermatology service. British Journal of Dermatology, 2017, 177, e141-e142.	1.4	5
451	First case of DRESS syndrome attributed to a spider bite. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 1135-1136.	2.0	4
452	Drug reaction with eosinophilia and systemic symptoms from ceftriaxone confirmed by positive patch test: An immunohistochemical study. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 808-810.	2.0	24
453	Correlation Between Serum Concentrations of N-Desmethylclozapine and Granulocyte Levels in Patients with Schizophrenia: A Retrospective Observational Study. CNS Drugs, 2017, 31, 991-997.	2.7	16
454	Association of the HLA-B alleles with carbamazepine-induced Stevens–Johnson syndrome/toxic epidermal necrolysis in the Javanese and Sundanese population of Indonesia: the important role of the HLA-B75 serotype. Pharmacogenomics, 2017, 18, 1643-1648.	0.6	36
455	Skin-Homing IL-13-Producing T Cells Expand in the Circulation of Patients with Drug Rash with Eosinophilia and Systemic Symptoms. Dermatology, 2017, 233, 242-249.	0.9	18
457	Drug reaction with eosinophilia and systemic symptoms (DRESS) successfully treated with tumor necrosis factor-1± inhibitor. JAAD Case Reports, 2017, 3, 332-335.	0.4	11
458	Leukapheresis in the management of drug rash with eosinophilia and systemic symptoms syndrome. Medicina Intensiva (English Edition), 2017, 41, 191-193.	0.1	0
459	Clinical features of drug reaction with eosinophilia and systemic symptoms (<scp>DRESS</scp>) syndrome: a study of 25 patients in Korea. International Journal of Dermatology, 2017, 56, 944-951.	0.5	31
460	Toxic epidermal necrolysis after dactinomycin and vincristine combination chemotherapy for nephroblastoma. Journal of Zhejiang University: Science B, 2017, 18, 649-652.	1.3	5
463	Patch testing in nonâ€immediate cutaneous adverse drug reactions: value of extemporaneous patch tests. Contact Dermatitis, 2017, 77, 297-302.	0.8	29
465	Difficult clinical management of antituberculosis DRESS syndrome complicated by MRSA infection. Medicine (United States), 2017, 96, e6346.	0.4	10
466	Cutaneous adverse drug reactions: Kids are not just little people. Clinics in Dermatology, 2017, 35, 566-582.	0.8	11
467	Cutaneous Drug Reactions in the Elderly. Drugs and Aging, 2017, 34, 655-672.	1.3	12
468	Overlapping DRESS and Stevens-Johnson Syndrome: Case Report and Review of the Literature. Case Reports in Dermatology, 2017, 9, 1-7.	0.3	14
469	Successful use of dabrafenib after the occurrence of drug rash with eosinophilia and systemic symptoms (DRESS) induced by vemurafenib. JAAD Case Reports, 2017, 3, 532-533.	0.4	10

#	Article	IF	CITATIONS
470	Rapid Involution of Pustules during Topical Steroid Treatment of Acute Generalized Exanthematous Pustulosis. Case Reports in Dermatology, 2017, 9, 135-139.	0.3	7
471	DRESS syndrome associated with splenic thrombosis. Annals of Allergy, Asthma and Immunology, 2017, 119, 463-464.	0.5	4
473	Severe erythema multiforme‑type drug eruption controlled by tumor necrosis factorâ€'α antagonist: A case study. Experimental and Therapeutic Medicine, 2017, 14, 5727-5732.	0.8	2
474	HLA-A*31:01 and carbamazepine-induced DRESS syndrom in a sample of North African population. Seizure: the Journal of the British Epilepsy Association, 2017, 53, 42-46.	0.9	19
475	The role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactions. Immunogenetics, 2017, 69, 617-630.	1.2	63
476	DRESS Syndrome: Drug Reaction With Eosinophilia and Systemic Symptoms. Pediatric Emergency Care, 2017, 33, 499-502.	0.5	25
477	Bibliometric analysis of literature on toxic epidermal necrolysis and Stevens-Johnson syndrome: 1940 – 2015. Orphanet Journal of Rare Diseases, 2017, 12, 14.	1.2	28
478	Ivermectin induced Steven–Johnsons syndrome: case report. BMC Research Notes, 2017, 10, 179.	0.6	12
479	Toxic Epidermal Necrolysis - A Case Report. The Journal of Critical Care Medicine, 2017, 3, 29-33.	0.3	1
480	Drugâ€induced liver and skin reactions: In need of a consensus definition. Hepatology, 2017, 65, 391-391.	3.6	3
482	Eosinophilic drug reactions detected by a prospective pharmacovigilance programme in a tertiary hospital. British Journal of Clinical Pharmacology, 2017, 83, 400-415.	1.1	27
483	Serum TARC levels are strongly correlated with blood eosinophil count in patients with drug eruptions. Allergology International, 2017, 66, 116-122.	1.4	27
484	Significant HLA class I type associations with aromatic antiepileptic drug (AED)-induced SJS/TEN are different from those found for the same AED-induced DRESS in the Spanish population. Pharmacological Research, 2017, 115, 168-178.	3.1	61
485	Cutaneous Manifestation of Drug Allergy and Hypersensitivity. Immunology and Allergy Clinics of North America, 2017, 37, 165-181.	0.7	16
486	Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in children: 20 years study in a tertiary care hospital. World Journal of Pediatrics, 2017, 13, 255-260.	0.8	23
487	Toxicodermias. EMC - DermatologÃa, 2017, 51, 1-13.	0.1	4
488	Three clinical pearls in the treatment of patients with seizures and comorbid psychiatric disorders. Mental Health Clinician, 2017, 7, 235-245.	0.5	4
489	Occurrence of Dermatomyositis Immediately after Mastectomy Subsequent to Severe Chemotherapeutic Drug Eruption. Internal Medicine, 2017, 56, 3379-3383.	0.3	7

#	Article	IF	CITATIONS
490	Drug rash with eosinophilia and systemic symptoms (DRESS) caused by phenytoin. BMJ Case Reports, 2017, 2017, bcr-2017-220835.	0.2	2
491	Drug Reaction with Eosinophilia and Systemic Symptoms. Chinese Medical Journal, 2017, 130, 943-949.	0.9	25
492	An illusion of septic shock: acute generalised exanthematous pustulosis with multiorgan dysfunction. BMJ Case Reports, 2017, 2017, bcr-2017-220612.	0.2	8
493	Acute interstitial nephritis and DRESS syndrome without eosinophilia associated with cefepime. BMJ Case Reports, 2017, 2017, bcr-2017-221401.	0.2	10
494	Presence of a single nucleotide polymorphism (RS3758581) in a boy with DRESS syndrome. Central-European Journal of Immunology, 2017, 42, 409-411.	0.4	4
495	Incidence, causative drugs, and economic consequences of drug-induced SJS, TEN, and SJS–TEN overlap and potential drug–drug interactions during treatment: a retrospective analysis at an Indonesian referral hospital. Therapeutics and Clinical Risk Management, 2017. Volume 13. 919-925.	0.9	12
496	Validation of a Rapid, Robust, Inexpensive Screening Method for Detecting the HLA-B*58:01 Allele in the Prevention of Allopurinol-Induced Severe Cutaneous Adverse Reactions. Allergy, Asthma and Immunology Research, 2017, 9, 79.	1.1	13
497	Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome associated with cefotaxime and clindamycin use in a 6 year-old boy: a case report. Pan African Medical Journal, 2017, 28, 218.	0.3	20
499	Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): An Interplay among Drugs, Viruses, and Immune System. International Journal of Molecular Sciences, 2017, 18, 1243.	1.8	170
500	New Insights into Drug Reaction with Eosinophilia and Systemic Symptoms Pathophysiology. Frontiers in Medicine, 2017, 4, 179.	1.2	39
501	Comparison between the <i>HLA-B</i> <mml:math <br="" xmlns:mml="http://www.w3.org/1998/Math/MathML">id="M1"><mml:msup><mml:mrow /><mml:mrow><mml:mo>â^—</mml:mo></mml:mrow></mml:mrow </mml:msup></mml:math> <i>58 : 01</i> Allele Single-Nucleotide Polymorphisms in Chromosome 6 for Prediction of Allopurinol-Induced Severe	and.9	12
502	Cutaneous Adverse Reactions. Journal of Immunology Research, 2017, 2017, 1-9. Management of the cutaneous adverse effects of antimelanoma therapy. Melanoma Management, 2017, 4, 187-202.	0.1	5
503	Treatments for Severe Cutaneous Adverse Reactions. Journal of Immunology Research, 2017, 2017, 1-9.	0.9	40
504	Immunohistopathological Findings of Severe Cutaneous Adverse Drug Reactions. Journal of Immunology Research, 2017, 2017, 1-5.	0.9	23
505	HLA Association with Drug-Induced Adverse Reactions. Journal of Immunology Research, 2017, 2017, 1-10.	0.9	111
506	Intensive Care in a Patient with Toxic Epidermal Necrolysis. Case Reports in Critical Care, 2017, 2017, 1-4.	0.2	4
507	Non-hemorrhage-related adverse effects of rivaroxaban. Archives of Medical Sciences Atherosclerotic Diseases, 2017, 2, 108-112.	0.5	14
508	Early Manifestations of Toxic Epidermal Necrolysis. Clinical Practice and Cases in Emergency Medicine, 2017, 1, 417-418.	0.1	1

~			~		
(† 17	ΓΑΤΙ	ON	- IS F	PO	RT

#	Article	IF	CITATIONS
509	Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis and Treatment With a Biologic: A Case Report. , 2017, 21, 16-060.		11
510	Collaboration in pharmacovigilance: lamotrigine and fatal severe cutaneous adverse reactions – a review of spontaneous reports. Therapeutics and Clinical Risk Management, 2017, Volume 13, 897-903.	0.9	5
511	Case report: atypical presentation of vancomycin induced DRESS syndrome: a case report and review of the literature. BMC Pulmonary Medicine, 2017, 17, 217.	0.8	13
512	Retrospective Analysis of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in 88 Chinese Patients. Chinese Medical Journal, 2017, 130, 1062-1068.	0.9	22
513	Severe cutaneous adverse drug reactions of Chinese inpatients: a meta-analysis. Anais Brasileiros De Dermatologia, 2017, 92, 345-349.	0.5	17
514	CYP2C19*2 status in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics and Personalized Medicine, 2017, Volume 10, 183-186.	0.4	5
515	Drug Reaction with Eosinophilia and Systemic Symptom Syndrome Induced by Lamotrigine. Annals of Dermatology, 2017, 29, 206.	0.3	3
516	Acute generalized exanthematous pustulosis induced by hydroxychloroquine: a case with atypical clinical presentation. Anais Brasileiros De Dermatologia, 2017, 92, 404-406.	0.5	18
517	Benznidazole Nanoformulates: A Chance to Improve Therapeutics for Chagas Disease. American Journal of Tropical Medicine and Hygiene, 2017, 97, 1469-1476.	0.6	30
518	Neosensitization to Multiple Drugs Following Valproate-Induced Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome. Psychiatry Investigation, 2017, 14, 518.	0.7	12
519	The measurement of drugâ€induced interferon γâ€releasing cells and lymphocyte proliferation in severe cutaneous adverse reactions. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 992-998.	1.3	30
520	DRESS syndrome induced by rifampicin. Therapie, 2018, 73, 441-443.	0.6	1
521	Hypersensitivity reactions to intravenous antibiotics in cystic fibrosis. Paediatric Respiratory Reviews, 2018, 27, 9-12.	1.2	13
522	A Case of Ceftriaxone-Induced Acute Generalized Exanthematous Pustulosis/Generalized Pustular Psoriasis Overlap. Case Reports in Dermatology, 2018, 10, 69-75.	0.3	9
523	Racial/ethnic variation and risk factors for allopurinol-associated severe cutaneous adverse reactions: a cohort study. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2017-212905.	0.5	29
524	A breathtaking <scp>DRESS</scp> due to amoxicillin–clavulanate presenting as polymorphic eruption of the pregnancy. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e436-e437.	1.3	7
525	<i>HLA-A*31:01</i> and Oxcarbazepine-Induced DRESS in a Patient With Seizures and Complete <i>DCX</i> Deletion. Pediatrics, 2018, 141, S434-S438.	1.0	12
526	Skin Testing for Suspected Iodinated Contrast Media Hypersensitivity. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1246-1254.	2.0	69

#	Article	IF	CITATIONS
527	Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: Case report of severe multiorgan involvement to perindopril/amlodipine combination antihypertensive. JAAD Case Reports, 2018, 4, 170-174.	0.4	5
528	Occupational allergic contact dermatitis caused by antibiotics in healthcare workers–Ârelationship with nonâ€immediate drug eruptions. Contact Dermatitis, 2018, 78, 281-286.	0.8	22
529	DRESS Syndrome due to benzylpenicillin with cross-reactivity to amoxicillin. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1766-1768.	2.0	10
530	Acute generalized exanthematous pustulosis simulating Stevens-Johnson syndrome/toxic epidermal necrolysis associated with the use of vismodegib. JAAD Case Reports, 2018, 4, 123-125.	0.4	8
531	Sensitivity and specificity of the lymphocyte transformation test in drug reaction with eosinophilia and systemic symptoms causality assessment. Clinical and Experimental Allergy, 2018, 48, 325-333.	1.4	49
532	Fatal DRESS syndrome under tocilizumab treatment for seronegative polyarthritis. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1048-1049.	2.0	7
533	The Combined Utility of ExÂVivo IFN-Î ³ Release Enzyme-Linked ImmunoSpot Assay and InÂVivo SkinÂTesting in Patients with Antibiotic-Associated Severe Cutaneous Adverse Reactions. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1287-1296.e1.	2.0	47
534	DRESS Syndrome Induced by Ranitidine. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1030-1031.	2.0	7
535	Successful Intravenous Immunoglobulin Treatment in Pediatric Severe DRESS Syndrome. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1238-1242.	2.0	31
536	Antituberculosis Drug-Associated DRESS: A Case Series. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1373-1380.	2.0	31
537	SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 38-69.	2.0	134
538	Influenza B virus infection and Stevens–Johnson syndrome. Pediatric Dermatology, 2018, 35, e45-e48.	0.5	11
539	Epidermal necrolysis French national diagnosis and care protocol (PNDS; protocole national de) Tj ETQq0 0 0 rgBT	- /Overlock 1.2	10 Tf 50 26
541	Unusual Clinical Manifestation of Laryngeal Edema in a Case of DRESS Syndrome. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 2108-2109.	2.0	2
542	Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome due to ethambutol. Médecine Et Maladies Infectieuses, 2018, 48, 302-305.	5.1	8
543	Severe Cutaneous Adverse Drug Reactions: Presentation, Risk Factors, and Management. Current Allergy and Asthma Reports, 2018, 18, 26.	2.4	38
544	The Frequency and Clinical Features of Hypersensitivity Reactions to Antiepileptic Drugs in Children: A Prospective Study. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 2043-2050.	2.0	18
545	Drug-Induced Skin Adverse Reactions: The Role of Pharmacogenomics in Their Prevention. Molecular Diagnosis and Therapy, 2018, 22, 297-314	1.6	15

#	Article	IF	CITATIONS
546	Acute pustular eruption following a Jarisch-Herxheimer reaction in the treatment of syphilis. JAAD Case Reports, 2018, 4, 259-261.	0.4	1
548	Association between HLA gene polymorphism and cutaneous adverse reactions caused by antiepileptic drugs. Experimental and Therapeutic Medicine, 2018, 15, 3399-3403.	0.8	3
549	Association Between HLA-B*1301 and Dapsone-Induced Cutaneous Adverse Drug Reactions. JAMA Dermatology, 2018, 154, 441.	2.0	44
550	A practical guide to thiopurine prescribing and monitoring in IBD. Frontline Gastroenterology, 2018, 9, 10-15.	0.9	53
551	Delayedâ€ŧype hypersensitivity reactions induced by proton pump inhibitors: A clinical and in vitro T ell reactivity study. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 221-229.	2.7	41
552	Common and uncommon adverse cutaneous reactions to erlotinib: a study of 20 Chinese patients with cancer. Cutaneous and Ocular Toxicology, 2018, 37, 96-99.	0.5	5
553	Fever, eosinophilia, and abnormal liver function are early signs suggestive of DRESS: A comparative study between DRESS and MPE. Dermatologica Sinica, 2018, 36, 25-29.	0.2	4
554	Cutaneous Reactions to Drugs. , 2018, , 53-72.		3
555	Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Clinical Reviews in Allergy and Immunology, 2018, 54, 147-176.	2.9	218
556	The minor alleles HCP5 rs3099844 A and PSORS1C1 rs3131003 G are associated with allopurinol-induced severe cutaneous adverse reactions in Han Chinese: a multicentre retrospective case-control clinical study. British Journal of Dermatology, 2018, 178, e191-e193.	1.4	7
557	Drug Hypersensitivity: Diagnosis, Genetics, and Prevention. Deutsches Ärzteblatt International, 2018, 115, 501-512.	0.6	35
558	Refractory cardiac myocarditis associated with drug rash with eosinophilia and systemic symptoms syndrome due to anti-bipolar disorder drugs: a case report. European Heart Journal - Case Reports, 2018, 2, yty100.	0.3	13
559	Eosinophilia and systemic symptoms with transient ageusia: a drug reaction caused by zonisamide. European Journal of Dermatology, 2018, 28, 523-524.	0.3	2
560	Variants of Erythema Multiforme: A Case Report and Literature Review. Cureus, 2018, 10, e3459.	0.2	11
561	Severe skin toxicity with organ damage under the combination of targeted therapy following immunotherapy in metastatic melanoma. Melanoma Research, 2018, 28, 451-457.	0.6	13
562	Lamotrigine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) during primary Epstein-Barr virus (EBV) infection. BMJ Case Reports, 2018, 2018, bcr-2017-222416.	0.2	5
563	Acute mucocutaneous methotrexate toxicity with marked tissue eosinophilia. BMJ Case Reports, 2018, 2018, bcr-2017-221489.	0.2	5
564	Drug-Induced Hypersensitivity Syndrome: A Clinical, Radiologic, and Histologic Mimic of Lymphoma. Case Reports in Hematology, 2018, 2018, 1-4.	0.3	6

#	Article	IF	CITATIONS
565	Stevensâ€Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: An analysis of the US Food and Drug Administration Adverse Event Reporting System. Epilepsia, 2018, 59, 2318-2324.	2.6	58
567	AGEP overlap induced by hydroxychloroquine: a case report and literature review. Journal of Community Hospital Internal Medicine Perspectives, 2018, 8, 360-362.	0.4	11
568	Stevens - Johnson Syndrome and Toxic Epidermal Necrolysis; Extensive Review of Reports of Drug-Induced Etiologies, and Possible Therapeutic Modalities. Open Access Macedonian Journal of Medical Sciences, 2018, 6, 730-738.	0.1	29
569	Granulomatous rhinitis secondary to feline leishmaniosis: report of an unusual presentation and therapeutic complications. Journal of Feline Medicine and Surgery Open Reports, 2018, 4, 205511691881137.	0.1	15
570	Hypouricemic Effects of Extracts From Agrocybe aegerita on Hyperuricemia Mice and Virtual Prediction of Bioactives by Molecular Docking. Frontiers in Pharmacology, 2018, 9, 498.	1.6	14
571	Optimal methods to detect DRESS (drug reaction with eosinophilia and systemic symptoms) syndrome by electronic medical records. Allergy Asthma & Respiratory Disease, 2018, 6, 149.	0.3	3
572	62-Year-Old Man With Fever and Pruritic Rash. Mayo Clinic Proceedings, 2018, 93, 1654-1658.	1.4	1
573	A case of Vogt-Koyanagi-Harada disease as a sequela of drug reaction with eosinophilia and systemic symptoms. JAAD Case Reports, 2018, 4, 863-865.	0.4	2
574	Cephalexin-induced acute generalized exanthematous pustulosis. Dermatology Reports, 2018, 10, 7686.	0.4	6
575	Actions of Inonotus obliquus against Hyperuricemia through XOD and Bioactives Screened by Molecular Modeling. International Journal of Molecular Sciences, 2018, 19, 3222.	1.8	16
576	A case of prolonged generalized exanthematous pustulosis caused by hydroxychloroquine—Literature review. Clinical Case Reports (discontinued), 2018, 6, 2391-2395.	0.2	16
577	Drug reaction with eosinophilia and systemic symptoms after daclizumab therapy in MS. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e479.	3.1	13
578	Meglumine antimoniate-induced DRESS: original case with a positive skin test. Acta Parasitologica, 2018, 63, 845-847.	0.4	2
579	Cutaneous side effects of molecularly targeted therapies for the treatment of solid tumors. Drugs in Context, 2018, 7, 1-11.	1.0	20
580	Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome Secondary to Furosemide: Case Report and Review of Literature. American Journal of Case Reports, 2018, 19, 163-170.	0.3	35
581	The influence of acute kidney injury on the outcome of Stevens–Johnson syndrome and toxic epidermal necrolysis: The prognostic value of KDIGO staging. PLoS ONE, 2018, 13, e0203642.	1.1	17
582	Genetic Basis of Delayed Hypersensitivity Reactions to Drugs in Jewish and Arab Populations. Pharmaceutical Research, 2018, 35, 211.	1.7	3
583	DRESS Syndrome: Drug Reaction with Eosinophilia and Systemic Symptoms/Drug-Induced Hypersensitivity Syndrome (DHS). , 2018, , 279-289.		0

#	Article	IF	CITATIONS
584	Successful Treatment of Stevens–Johnson Syndrome with Cyclosporine and Corticosteroid. Canadian Journal of Hospital Pharmacy, 2018, 71, .	0.1	7
585	Successful Treatment of Methampyrone-Induced Toxic Epidermal Necrolysis with Therapeutic Plasma Exchange. Case Reports in Medicine, 2018, 2018, 1-4.	0.3	3
586	Occurrence of Drug Eruption following Tigecycline Treatment in a Japanese Patient. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2018, 44, 24-28.	0.0	0
587	Antituberculosis Drug-Induced Fixed Drug Eruption: A Case Report. Drug Safety - Case Reports, 2018, 5, 23.	0.9	3
588	Clinical Pharmacogenomics. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1561-1571.	2.2	18
589	Life-threatening dermatoses: Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Impact on the Spanish public health system (2010-2015). PLoS ONE, 2018, 13, e0198582.	1.1	16
590	A diagnosis of Stevens-Johnson Syndrome (SJS) in a patient presenting with superficial keratitis. American Journal of Ophthalmology Case Reports, 2018, 11, 167-169.	0.4	5
591	Stevens-Johnson syndrome–like eruption from palbociclib in a patient with metastatic breast cancer. JAAD Case Reports, 2018, 4, 452-454.	0.4	17
592	Association between HLA-B Alleles and Carbamazepine-Induced Maculopapular Exanthema and Severe Cutaneous Reactions in Thai Patients. Journal of Immunology Research, 2018, 2018, 1-11.	0.9	55
593	Overlap Between DRESS Syndrome and Exanthema Induced by Sulfadiazine in a Patient Treated With Sulfamethoxazole: Utility of the Lymphocyte Transformation Test for Identification of the Culprit Drug. Journal of Investigational Allergology and Clinical Immunology, 2018, 28, 132-134.	0.6	5
594	The Epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in China. Journal of Immunology Research, 2018, 2018, 1-10.	0.9	25
596	Clinical Features and Treatment Outcomes among Children with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A 20-Year Study in a Tertiary Referral Hospital. Dermatology Research and Practice, 2018, 2018, 1-9.	0.3	22
597	Recent Advances in Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms. Journal of Immunology Research, 2018, 2018, 1-10.	0.9	44
598	An Updated Review of the Molecular Mechanisms in Drug Hypersensitivity. Journal of Immunology Research, 2018, 2018, 1-22.	0.9	111
599	Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies. Journal of Immunology Research, 2018, 2018, 1-9.	0.9	41
600	Ivermectin-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. JAAD Case Reports, 2018, 4, 524-527.	0.4	8
601	Clinical, Viral and Genetic Characteristics of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) in Shanghai, China. Acta Dermato-Venereologica, 2018, 98, 401-405.	0.6	24
602	A Rare Presentation of Clozapine-Induced DRESS Syndrome. Case Reports in Medicine, 2018, 2018, 1-3.	0.3	9

#	Article	IF	CITATIONS
603	Intravenous Immunoglobulin May Be Beneficial as an Add-on Therapy in DRESS. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1243-1245.	2.0	5
604	Diclofenac induced drug rash with eosinophilia and systemic symptoms. Therapie, 2018, 73, 551-553.	0.6	2
605	Drug Reaction with Eosinophilia and Systemic Symptoms Associated with Reactivation of Epstein-Barr Virus and/or Cytomegalovirus Leading to Hemophagocytic Syndrome in One of Two Patients. Annals of Dermatology, 2018, 30, 71.	0.3	13
606	Acute localized exanthematous pustulosis (ALEP) caused by lamotrigine. JAAD Case Reports, 2018, 4, 645-647.	0.4	12
607	PSORS1C1 Hypomethylation Is Associated with Allopurinol-Induced Severe Cutaneous Adverse Reactions during Disease Onset Period: A Multicenter Retrospective Case-Control Clinical Study in Han Chinese. Frontiers in Pharmacology, 2017, 8, 923.	1.6	10
608	Stevens‑Johnsons syndrome or drug‑induced lupus ‑ a clinical dilemma: A case report and review of the literature. Biomedical Reports, 2018, 9, 37-41.	0.9	8
609	Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies. Cancer Management and Research, 2018, Volume 10, 1259-1273.	0.9	109
610	Vancomycin-Induced DRESS Syndrome: An Important Concern in Orthopedic Surgery. Case Reports in Orthopedics, 2018, 2018, 1-5.	0.1	5
611	A case report of toxic epidermal necrolysis associated with AZD-9291. Drug Design, Development and Therapy, 2018, Volume 12, 2163-2167.	2.0	15
612	Physiology of Hyperuricemia and Urate-Lowering Treatments. Frontiers in Medicine, 2018, 5, 160.	1.2	176
613	Cordycepin, a Characteristic Bioactive Constituent in Cordyceps militaris, Ameliorates Hyperuricemia through URAT1 in Hyperuricemic Mice. Frontiers in Microbiology, 2018, 9, 58.	1.5	26
614	DRESS Syndrome and Daclizumab Failure—Were Potentially Dangerous Signs Missed in Clinical Trials?. Drug Target Insights, 2018, 12, 117739281878513.	0.9	9
615	Stevens–Johnson syndrome/toxic epidermal necrolysis and erythema multiforme drug-related hospitalisations in a national administrative database. Clinical and Translational Allergy, 2018, 8, 2.	1.4	23
616	A meta-analysis of cyclosporine treatment for Stevens–Johnson syndrome/toxic epidermal necrolysis. Journal of Inflammation Research, 2018, Volume 11, 135-142.	1.6	58
617	Prevalence, risk factors, and mortality outcome in the drug reaction with eosinophilia and systemic symptoms patients with cardiac involvement. International Journal of Dermatology, 2018, 57, 1187-1191.	0.5	17
618	Reticular rash in drug reaction with eosinophilia and systemic symptoms syndrome: A clue to parvovirus B19 reactivation?. JAAD Case Reports, 2018, 4, 728-732.	0.4	2
620	Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome in two young children: the importance of an early diagnosis. Italian Journal of Pediatrics, 2018, 44, 93.	1.0	19
621	Onset of Hemophagocytic Lymphohistiocytosis during Piperacillin-Tazobactam Therapy in Three Children with Acute Focal Bacterial Nephritis. Tohoku Journal of Experimental Medicine, 2018, 245, 55-59.	0.5	5

#	Article	IF	CITATIONS
622	Analysis of HLA-B Allelic Variation and IFN-Î ³ ELISpot Responses in Patients with Severe Cutaneous Adverse Reactions Associated with Drugs. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 219-227.e4.	2.0	36
623	Applications of Immunopharmacogenomics: Predicting, Preventing, and Understanding Immune-Mediated Adverse Drug Reactions. Annual Review of Pharmacology and Toxicology, 2019, 59, 463-486.	4.2	42
624	Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis in Association with Commonly Prescribed Drugs in Outpatient Care Other than Anti-Epileptic Drugs and Antibiotics: A Population-Based Case–Control Study. Drug Safety, 2019, 42, 55-66.	1.4	30
625	<i>HLA-B*58:01</i> Genotyping to Prevent Cases of DRESS and SJS/TEN in East Asians Treated with Allopurinol—A Canadian Missed Opportunity. Journal of Cutaneous Medicine and Surgery, 2019, 23, 595-601.	0.6	12
626	Fulminant Type 1 Diabetes Mellitus Caused by Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS): A Case Report and Review of the Literature. Frontiers in Endocrinology, 2019, 10, 474.	1.5	13
627	Identification of drug-specific public TCR driving severe cutaneous adverse reactions. Nature Communications, 2019, 10, 3569.	5.8	83
628	Drug-induced severe cutaneous adverse reactions. Annals of Allergy, Asthma and Immunology, 2019, 123, 483-487.	0.5	30
629	Outcomes of Stevens–Johnson syndrome and toxic epidermal necrolysis in HIV-infected patients when using systemic steroids and/or intravenous immunoglobulins in Pietermaritzburg, South Africa. Southern African Journal of HIV Medicine, 2019, 20, 944.	0.3	8
630	Case Reports of DRESS Syndrome and Symptoms Consistent with DRESS Syndrome Following Treatment with Recently Marketed Monoclonal Antibodies. Autoimmune Diseases, 2019, 2019, 1-6.	2.7	10
631	Ocular manifestations in patients with Stevens–Johnson syndrome in Malawi—review of the literature illustrated by clinical cases. Graefe's Archive for Clinical and Experimental Ophthalmology, 2019, 257, 2343-2348.	1.0	6
632	Unique Clinical Characteristics and Prognosis of Allopurinol-Induced Severe Cutaneous Adverse Reactions. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2739-2749.e3.	2.0	17
633	Drugs as a Frequent Cause of Acute Rash in Patients after CD34+-Selected Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 2172-2180.	2.0	3
634	Mutant GNLY is linked to Stevens–Johnson syndrome and toxic epidermal necrolysis. Human Genetics, 2019, 138, 1267-1274.	1.8	3
635	Pulmonary Manifestations of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome: A Systematic Review. BioMed Research International, 2019, 2019, 1-10.	0.9	60
636	>A Unique Case Of Tenofovir-Induced DRESS Syndrome Associated With Raynaud's Of The Tongue. International Journal of General Medicine, 2019, Volume 12, 381-385.	0.8	3
637	Co-Occurrence of Multiple Endocrine Abnormalities Induced by the DIHS/DRESS. International Journal of Endocrinology, 2019, 2019, 1-8.	0.6	9
638	Severe skin reactions: clinical picture, epidemiology, etiology, pathogenesis, and treatment. Allergo Journal International, 2019, 28, 311-326.	0.9	15
639	Lymphocyte Transformation Test (LTT) in Allergy to Benznidazole: A Promising Approach. Frontiers in Pharmacology, 2019, 10, 469.	1.6	7

		CITATION REPORT		
#	Article		IF	Citations
640	Important Points in Toxic Epidermal Necrolysis Management. Oman Medical Journal, 2019, 34, 357	-358.	0.3	1
641	Drug-induced liver injury. Nature Reviews Disease Primers, 2019, 5, 58.		18.1	409
642	A Randomized, Double-Blind, Non-Inferiority Study of Febuxostat Versus Allopurinol in Hyperuricem Chinese Subjects With or Without Gout. Rheumatology and Therapy, 2019, 6, 543-557.	iic	1.1	6
643	Allopurinol-Induced Toxic Epidermal Necrolysis. Drug Safety - Case Reports, 2019, 6, 8.		0.9	3
644	Human leukocyte antigen-associated severe cutaneous adverse drug reactions: from bedside to be and beyond. Asia Pacific Allergy, 2019, 9, e20.	nch	0.6	6
645	Drug reaction with eosinophilia and systemic symptoms in a child with N-methyl-d-aspartate recept encephalitis. Baylor University Medical Center Proceedings, 2019, 32, 603-604.	or	0.2	0
646	Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome Associated with Ethambutol u Case Report. Current Drug Safety, 2019, 14, 249-251.	se: A	0.3	2
647	Contrast-induced generalized bullous fixed drug eruption resembling Stevens-Johnson syndrome. Baylor University Medical Center Proceedings, 2019, 32, 601-602.		0.2	10
648	Prosthetic Replacement of the Ocular Surface Ecosystem Treatment for Ocular Surface Disease in Pediatric Patients With Stevens-Johnson Syndrome. American Journal of Ophthalmology, 2019, 201	1, 1-8.	1.7	19
649	Drugâ€induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms to lamotrigine differs from that due to other drugs. Journal of Dermatology, 2019, 46, 226-233.	due	0.6	16
650	Adverse Cutaneous Drug Reactions Associated with Old- and New- Generation Antiepileptic Drugs Using the Japanese Pharmacovigilance Database. Clinical Drug Investigation, 2019, 39, 363-368.		1.1	22
651	Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatmer with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series. , 2019, 7, 4.	ht		18
652	Phenotypes of Severe Cutaneous Adverse Reactions Caused by Nonsteroidal Anti-inflammatory Dru Allergy, Asthma and Immunology Research, 2019, 11, 212.	ıgs.	1.1	13
653	Severe Cutaneous Adverse Reactions in Korean Pediatric Patients: A Study From the Korea SCAR Registry. Allergy, Asthma and Immunology Research, 2019, 11, 241.		1.1	22
654	Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS): How Far Have We Come?. Amer Journal of Clinical Dermatology, 2019, 20, 217-236.	ican	3.3	48
655	Markers of systemic involvement and death in hospitalized cancer patients with severe cutaneous adverse reactions. Journal of the American Academy of Dermatology, 2019, 80, 608-616.		0.6	8
656	Drug reaction with eosinophilia and systemic symptoms syndrome after total knee arthroplasty infection and placement of antibiotic spacer. Arthroplasty Today, 2019, 5, 148-151.		0.8	6
657	High and variable population prevalence of HLAâ€B*56:02 in indigenous Australians and relation to phenytoinâ€associated drug reaction with eosinophilia and systemic symptoms. British Journal of Clinical Pharmacology, 2019, 85, 2163-2169.		1.1	19

#	Article	IF	CITATIONS
658	A Rare Case of DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) Syndrome with Cholecystitis in a Patient on Levetiracetam. Cureus, 2019, 11, e4245.	0.2	2
659	KCNQ2 related early-onset epileptic encephalopathies in Chinese children. Journal of Neurology, 2019, 266, 2224-2232.	1.8	13
661	Oxacillin-Induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). American Journal of Case Reports, 2019, 20, 345-348.	0.3	7
662	Vancomycin-associated drug-induced hypersensitivity syndrome. Journal of the American Academy of Dermatology, 2019, 81, 123-128.	0.6	25
663	Carbamazepine-induced DRESS syndrome leading to reversible myocarditis in a child. Central-European Journal of Immunology, 2019, 44, 102-105.	0.4	5
664	Piperacillin/Tazobactam as Cause of Acute Generalized Exanthematous Pustulosis. Case Reports in Dermatological Medicine, 2019, 2019, 1-3.	0.1	1
665	Reintroduction of dabrafenib after previous vemurafenib-induced DRESS: Not always safe!. JAAD Case Reports, 2019, 5, 422-423.	0.4	4
666	Mechanisms of Severe Cutaneous Adverse Reactions: Recent Advances. Drug Safety, 2019, 42, 973-992.	1.4	66
667	Drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): An update in 2019. Allergology International, 2019, 68, 301-308.	1.4	184
668	A review of cutaneous hypersensitivity reactions in infants: From common to concerning. Pediatric Dermatology, 2019, 36, 274-282.	0.5	14
669	Are drug intradermal tests dangerous to explore crossâ€reactivity and coâ€sensitization in DRESS?. British Journal of Dermatology, 2019, 181, 611-612.	1.4	16
670	Pseudo-allergic reaction caused by Qingkailing injection partially via the PI3K-Rac1 signaling pathway in RBL-2H3 cells. Toxicology Research, 2019, 8, 353-360.	0.9	5
671	EASL Clinical Practice Guidelines: Drug-induced liver injury. Journal of Hepatology, 2019, 70, 1222-1261.	1.8	629
672	Personal genome testing on physicians improves attitudes on pharmacogenomic approaches. PLoS ONE, 2019, 14, e0213860.	1.1	7
674	Translating Pharmacogenetics and Pharmacogenomics to the Clinic: Progress in Human and Veterinary Medicine. Frontiers in Veterinary Science, 2019, 6, 22.	0.9	12
675	A Case Report of Fulminant Type 1 Diabetes Mellitus Caused by Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Complicated by Iodine-Induced Thyrotoxicosis. Diabetes Therapy, 2019, 10, 1145-1150.	1.2	1
676	Increased Type 2 Innate Lymphoid Cells inÂPatients with Drug Reaction with EosinophiliaÂand Systemic Symptoms Syndrome. Journal of Investigative Dermatology, 2019, 139, 1722-1731.	0.3	19
677	Pediatric Drug Hypersensitivity. Current Allergy and Asthma Reports, 2019, 19, 11.	2.4	8

#	Article	IF	CITATIONS
678	Phenotypes and Natural Evolution of Drug Hypersensitivity. Current Treatment Options in Allergy, 2019, 6, 27-41.	0.9	2
679	Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms severity score: A useful tool for assessing disease severity and predicting fatal cytomegalovirus disease. Journal of the American Academy of Dermatology, 2019, 80, 670-678.e2.	0.6	87
680	HIV-Related Skin Disease in the Era of Antiretroviral Therapy: Recognition and Management. American Journal of Clinical Dermatology, 2019, 20, 423-442.	3.3	17
681	Anticancer Agent-Induced Life-Threatening Skin Toxicities: A Database Study of Spontaneous Reporting Data. Oncologist, 2019, 24, 266-272.	1.9	3
682	Mepolizumab rescue therapy for acute pneumonitis secondary to DRESS. BMJ Case Reports, 2019, 12, e231355.	0.2	11
683	Genetic testing for prevention of severe drug-induced skin rash. The Cochrane Library, 2019, 7, CD010891.	1.5	7
684	An atypical presentation of toxic epidermal necrolysis without mucosal involvement. Medical Journal Armed Forces India, 2019, 78, 106-108.	0.3	2
685	Causative drugs for drug-induced cutaneous reactions in central China: a 608-case analysis. Anais Brasileiros De Dermatologia, 2019, 94, 664-670.	0.5	12
686	Drug-induced hypersensitivity syndrome with myocardial involvement treated with tofacitinib. JAAD Case Reports, 2019, 5, 1018-1026.	0.4	24
688	Diffuse Alveolar Hemorrhage in the Setting of an Acute Exacerbation of Chronic Hypersensitivity Pneumonitis Due to Drug Rash With Eosinophilia and Systemic Symptoms: A Case Report. Clinical Pulmonary Medicine, 2019, 26, 181-183.	0.3	2
690	Risk of Acute Myocardial Infarction Among New Users of Allopurinol According to Serum Urate Level: A Nested Case-Control Study. Journal of Clinical Medicine, 2019, 8, 2150.	1.0	8
691	Duloxetine-Associated Acute Laryngeal Dystonia. Journal of Clinical Psychopharmacology, 2019, 39, 678-679.	0.7	2
692	Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome Related to Aripiprazole Therapy. Journal of Clinical Psychopharmacology, 2019, 39, 691-693.	0.7	7
693	Severe Extrapyramidal Symptoms in a Patient with Niemann-Pick Type C Disease After a Long-Acting Injection of Risperidone. Journal of Clinical Psychopharmacology, 2019, 39, 677-678.	0.7	0
694	Colonic Involvement of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Rare Cause of Gastrointestinal Bleeding. ACG Case Reports Journal, 2019, 6, e00242.	0.2	2
696	Recurrence of DRESS syndrome to escitalopram or neosensitization?. Therapie, 2019, 74, 504-506.	0.6	2
697	Valaciclovir: a culprit drug for drug reaction with eosinophilia and systemic symptoms not to be neglected. Three cases. British Journal of Dermatology, 2019, 180, 666-667.	1.4	6
698	Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease. International Urology and Nephrology, 2019, 51, 467-473.	0.6	31

# 699	ARTICLE Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). , 2019, , 87-104.	IF	CITATIONS
700	Natural compounds with xanthine oxidase inhibitory activity: A review. Chemical Biology and Drug Design, 2019, 93, 387-418.	1.5	85
701	Advances in Diagnosis and Management of Cutaneous Adverse Drug Reactions. , 2019, , .		6
702	HLA-B*5701 and HLA-B*5801 in an Indian patient with anti-epileptics induced cutaneous adverse drug reactions. European Journal of Clinical Pharmacology, 2019, 75, 599-601.	0.8	2
703	Differentiation of angioimmunoblastic T-cell lymphoma from DRESS syndrome. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1684-1686.e1.	2.0	3
704	Efficacy and tolerability of desensitization in the treatment of delayed drug hypersensitivities to anti-tuberculosis medications. Respiratory Medicine, 2019, 147, 44-50.	1.3	22
706	An Interesting Case of Carbamazepine-Induced Stevens–Johnson Syndrome. Drug Safety - Case Reports, 2019, 6, 1.	0.9	7
707	Drugâ€induced liver injury with skin reactions: Drugs and host risk factors, clinical phenotypes and prognosis. Liver International, 2019, 39, 802-811.	1.9	23
708	Prevalence and Clinical Features of Drug Reactions With Eosinophilia and Systemic Symptoms Syndrome Caused by Antituberculosis Drugs: A Retrospective Cohort Study. Allergy, Asthma and Immunology Research, 2019, 11, 90.	1.1	19
709	Incidence of Stevens-Johnson syndrome/toxic epidermal necrolysis among new users of different individual drugs in a European population: a case-population study. European Journal of Clinical Pharmacology, 2019, 75, 237-246.	0.8	16
710	<scp>HLA</scp> Alleles and <i><scp>CYP</scp>2C9*3</i> as Predictors of Phenytoin Hypersensitivity in East Asians. Clinical Pharmacology and Therapeutics, 2019, 105, 476-485.	2.3	53
711	Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome Identified in the Electronic Health Record Allergy Module. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 633-640.	2.0	78
712	Drug reaction with eosinophilia and systemic symptoms may occur within 2Âweeks of drug exposure: A retrospective study. Journal of the American Academy of Dermatology, 2020, 82, 606-611.	0.6	50
713	Multiple Drug Hypersensitivity Syndrome to Antituberculosis Drugs: A Case Report. Journal of Investigational Allergology and Clinical Immunology, 2020, 30, 70-71.	0.6	5
714	Pediatric drug reaction with eosinophilia and systemic symptoms: A systematic review of the literature. Pediatric Dermatology, 2020, 37, 124-129.	0.5	35
715	The rash that presents as a red swollen face. Clinics in Dermatology, 2020, 38, 63-78.	0.8	7
716	Diagnostic and prognostic assessment of suspected drugâ€induced liver injury in clinical practice. Liver International, 2020, 40, 6-17.	1.9	30
717	Fatal sulfasalazine-induced DRESS complicated by HHV-6 reactivation and hemophagocytic lymphohistiocytosis. European Journal of Clinical Pharmacology, 2020, 76, 467-468.	0.8	5

#	Article	IF	CITATIONS
718	Severe Cutaneous Adverse Drug Reactions Associated with Allopurinol: An Analysis of Spontaneous Reporting System in Southern Italy. Drugs - Real World Outcomes, 2020, 7, 41-51.	0.7	23
719	Serum soluble Fas ligand levels and peripheral blood lymphocyte subsets in patients with drug-induced maculopapular rashes, dress, and viral exanthemas. Allergologia Et Immunopathologia, 2020, 48, 339-347.	1.0	2
720	DRESS syndrome in response to Denosumab: First documented case report. Bone Reports, 2020, 12, 100239.	0.2	7
721	Lateâ€onset interstitial nephritis in a patient with drugâ€induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Journal of Dermatology, 2020, 47, 174-177.	0.6	3
722	The role of drug, dose, and the tolerance/intolerance of new drugs in multiple drug hypersensitivity syndrome. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1178-1187.	2.7	18
723	Approach to Patients with Eosinophilia. Medical Clinics of North America, 2020, 104, 1-14.	1.1	40
724	Drug reaction with eosinophilia and systemic symptoms (DRESS) with severe and atypical lung involvement. Radiology Case Reports, 2020, 15, 2178-2182.	0.2	2
725	Drug rash with eosinophilia and systemic symptoms and severe renal injury induced by proton pump inhibitor therapy. Medicine (United States), 2020, 99, e22509.	0.4	7
726	Acute generalized exanthematous pustulosis caused by iopamidol with recurrence on rechallenge with iopromide. JAAD Case Reports, 2020, 6, 964-966.	0.4	4
727	A case report of toxic epidermal necrolysis (TEN) in a patient with COVID-19 treated with hydroxychloroquine: are these two partners in crime?. Clinical and Molecular Allergy, 2020, 18, 19.	0.8	23
728	Tosufloxacin-induced acute generalized exanthematous pustulosis confirmed by a drug-induced lymphocyte stimulation test. JAAD Case Reports, 2020, 6, 1016-1018.	0.4	3
729	Chlorpromazine-induced Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome. Indian Journal of Psychological Medicine, 2020, 42, 99-101.	0.6	3
730	Carbamazepine-Induced Toxic Epidermal Necrolysis Managed by Mobile Teledermatology in COVID-19 Pandemic in Rural Nepal. Case Reports in Dermatological Medicine, 2020, 2020, 1-3.	0.1	5
731	Acute generalised exanthematous pustulosis associated with shock. BMJ Case Reports, 2020, 13, e235846.	0.2	3
732	DRESS syndrome following furosemide administration: An unusual association. Nephrologie Et Therapeutique, 2020, 16, 437-438.	0.2	5
733	Drug-related relapses in drug reaction with eosinophilia and systemic symptoms (DRESS). Clinical and Translational Allergy, 2020, 10, 52.	1.4	15
734	Lamotrigine induced toxic epidermal necrolysis: A case report. Annals of Medicine and Surgery, 2020, 60, 468-470.	0.5	2
735	<scp>COVID</scp> â€19 and immunosuppressive therapy in dermatology. Dermatologic Therapy, 2020, 33, e14140.	0.8	9

#	Article	IF	Citations
736	Myeloperoxidase Modulates Inflammation in Generalized Pustular Psoriasis and Additional Rare Pustular Skin Diseases. American Journal of Human Genetics, 2020, 107, 527-538.	2.6	53
737	Allopurinol-Induced Drug Reaction With Eosinophilia and Systemic Symptoms. Advanced Emergency Nursing Journal, 2020, 42, 108-118.	0.2	5
738	Disseminated intravascular coagulation: A devastating systemic disorder of special concern with <scp>COVID</scp> â€19. Dermatologic Therapy, 2020, 33, e14053.	0.8	16
739	Pharmacogenetic Testing for Prevention of Severe Cutaneous Adverse Drug Reactions. Frontiers in Pharmacology, 2020, 11, 969.	1.6	38
740	Drug reaction with eosinophilia and systemic symptoms syndrome in a patient with COVIDâ€19. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e768-e700.	1.3	19
741	HLA-B*58:01 association in allopurinol-induced severe cutaneous adverse reactions: the implication of ethnicity and clinical phenotypes in multiethnic Malaysia. Pharmacogenetics and Genomics, 2020, 30, 153-160.	0.7	8
742	Trimethoprimâ€induced drug reaction with eosinophilia and systemic symptoms (DRESS) associated with reactivation of human herpes virusâ€6 (HHVâ€6) leading to acute liver failure. Clinical Case Reports (discontinued), 2020, 8, 2568-2573.	0.2	4
743	Overlap between hemophagocytic lymphohistiocytosis and drug reaction and eosinophilia with systemic symptoms: a review. International Journal of Dermatology, 2021, 60, 925-932.	O.5	9
744	Drug induced liver injury: an update. Archives of Toxicology, 2020, 94, 3381-3407.	1.9	125
745	Predictive biomarkers for cytomegalovirus reactivation before and after immunosuppressive therapy: A single-institution retrospective long-term analysis of patients with drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic syndrome (DRESS). International lournal of Infectious Diseases. 2020, 100, 239-246.	1.5	12
746	Development of Fulminant Type 1 Diabetes Mellitus in a Patient with DRESS Syndrome. Case Reports in Endocrinology, 2020, 2020, 1-5.	0.2	3
747	A case of toxic epidermal necrosis–like cutaneous eruption as the first manifestation and clue to the diagnosis of systemic lupus erythematosus: A case report. SAGE Open Medical Case Reports, 2020, 8, 2050313X2094042.	0.2	0
748	Alectinib-associated drug reaction with eosinophilia and systemic symptoms syndrome. JAAD Case Reports, 2020, 6, 1339-1341.	0.4	3
749	Triad of acute generalized exanthematous pustulosis, delirium, and lactic acidosis due to azithromycin. JAAD Case Reports, 2020, 6, 1254-1257.	0.4	3
750	Liver transplantation after DRESS syndrome: A case report and review of the literature. Clinical Case Reports (discontinued), 2020, 8, 3008-3012.	0.2	4
751	Vajra Bhasma, Ayurvedic medicine: a rare and unusual cause of Lyell's syndrome and its successful management. BMJ Case Reports, 2020, 13, e237891.	0.2	0
752	Toxic Epidermal Necrolysis (TEN)/Stevens-Johnson Syndrome (SJS) Epidemiology and Mortality Rate at King Fahad Specialist Hospital (KFSH) in Qassim Region of Saudi Arabia: A Retrospective Study. Dermatology Research and Practice, 2020, 2020, 1-3.	0.3	8
753	CXCL10/IPâ€10, an early biomarker for late sequelae in DRESS?. British Journal of Dermatology, 2020, 183, 804-805.	1.4	0

#	Article	IF	CITATIONS
754	DRESS syndrome: an important differential for eosinophilia with systemic organ dysfunction. BMJ Case Reports, 2020, 13, e234251.	0.2	4
755	Lamotrigine-induced DRESS with purpuric lesions in the oral mucosa. JAAD Case Reports, 2020, 6, 383-385.	0.4	3
756	Ixekizumab for treatment of refractory acute generalized exanthematous pustulosis caused by hydroxychloroquine. JAAD Case Reports, 2020, 6, 634-636.	0.4	7
757	A case of cefditorenâ€induced acute generalized exanthematous pustulosis during COVIDâ€19 pandemics. Severe cutaneous adverse reactions are an issue. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e537-e539.	1.3	12
758	An update on CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 723-734.	1.5	12
759	Clozapine-related drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a systematic review. Expert Review of Clinical Pharmacology, 2020, 13, 875-883.	1.3	26
760	Drug reaction with eosinophilia and systemic symptoms syndrome induced by apixaban. Dermatologic Therapy, 2020, 33, e13719.	0.8	4
761	Multidisciplinary care in Stevens-Johnson syndrome. Therapeutic Advances in Chronic Disease, 2020, 11, 204062231989446.	1.1	34
762	Commercial Cannabinoid Oil-Induced Stevens-Johnson Syndrome. Case Reports in Ophthalmological Medicine, 2020, 2020, 1-5.	0.3	13
763	Genetic Diversity of HLA Class I and Class II Alleles in Thai Populations: Contribution to Genotype-Guided Therapeutics. Frontiers in Pharmacology, 2020, 11, 78.	1.6	38
764	Update on penicillin allergy delabeling. Current Opinion in Pediatrics, 2020, 32, 321-327.	1.0	10
765	Fatal pediatric Stevens–Johnson syndrome/toxic epidermal necrolysis. Medicine (United States), 2020, 99, e19431.	0.4	5
766	Severe Cutaneous Adverse Reactions to Drugs in Latin America: The RACGRAD Study. Journal of Investigational Allergology and Clinical Immunology, 2021, 31, 322-331.	0.6	6
767	Genetic and clinical risk factors associated with phenytoinâ€induced cutaneous adverse drug reactions in Thai population. Pharmacoepidemiology and Drug Safety, 2020, 29, 565-574.	0.9	23
768	Agranulocytosisâ€complicated DRESS with medullar HHVâ€6 replication. Clinical Case Reports (discontinued), 2020, 8, 1928-1931.	0.2	2
769	Dysregulation of microRNA expression in the skin during cutaneous adverse drug reactions. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 3279-3283.	2.7	2
770	Stevens-Johnson syndrome and toxic epidermal necrolysis in pregnant patients: A systematic review. International Journal of Women's Dermatology, 2020, 6, 239-247.	1.1	3
771	Allopurinol prescription patterns among patients in a Saudi tertiary care centre. Journal of Taibah University Medical Sciences, 2020, 15, 185-189.	0.5	1

#	Article	IF	CITATIONS
772	Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. Clinics in Dermatology, 2020, 38, 702-711.	0.8	38
773	Clinical Utility of <i>HLA-B*58:01</i> Genotyping to Prevent Allopurinol-Induced SJS/TEN. Hospital Pharmacy, 2021, 56, 660-663.	0.4	4
774	A case of drug reaction with eosinophilia and systemic symptoms (DRESS) without a typical precipitant. Medical Journal of Australia, 2020, 212, 300.	0.8	6
775	IVIG and under Burn Unit Care Yield Favorable Outcomes in Pediatric Patients with Toxic Epidermal Necrolysis: A Case Report and Literature Review. Case Reports in Dermatological Medicine, 2020, 2020, 1-5.	0.1	2
777	The interferonâ€Î³â€induced protein 10/CXCR3 axis is associated with human herpesvirusâ€6 reactivation and the development of sequelae in drug reaction with eosinophilia and systemic symptoms*. British Journal of Dermatology, 2020, 183, 909-919.	1.4	21
778	Precision Medicine in Non-Communicable Diseases. High-Throughput, 2020, 9, 3.	4.4	9
779	<p>Immediate Reactions to Fluorescein and Indocyanine Green in Retinal Angiography: Review of Literature and Proposal for Patient's Evaluation</p> . Clinical Ophthalmology, 2020, Volume 14, 171-178.	0.9	34
780	DRESS syndrome after lamotrigine and valproic acid use in a bipolar patient: a case report. European Journal of Psychiatry, 2020, 34, 160-163.	0.7	1
781	Association of HLA genotypes with phenytoin induced severe cutaneous adverse drug reactions in Thai children. Epilepsy Research, 2020, 162, 106321.	0.8	18
782	Drug reaction with eosinophilia and systemic symptoms (DRESS) in the pediatric population: A systematic review of the literature. Journal of the American Academy of Dermatology, 2020, 83, 1323-1330.	0.6	31
783	Apremilast-associated drug reaction with eosinophilia and systemic symptoms. JAAD Case Reports, 2020, 6, 302-304.	0.4	2
784	Generalized pustular figurate erythema: A newly delineated severe cutaneous drug reaction linked with hydroxychloroquine. Dermatologic Therapy, 2020, 33, e13380.	0.8	54
785	Rapid recovery of postnivolumab vemurafenib-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome after tocilizumab and infliximab administration. , 2020, 8, e000388.		14
786	A Novel Treatment for a Rare Cause of Cardiogenic Shock. JACC: Case Reports, 2020, 2, 1461-1465.	0.3	5
787	Atypical Manifestation of DRESS Syndrome. Case Reports in Gastrointestinal Medicine, 2020, 2020, 1-3.	0.2	1
788	Interface dermatitis as an indicator of hepatic involvement in drug reaction with eosinophilia and systemic symptoms (<scp>DRESS</scp>). Journal of Cutaneous Pathology, 2020, 47, 800-808.	0.7	0
789	Association of interleukin-6 and tumor necrosis factor-α with mortality in hospitalized patients with cancer. Journal of the American Academy of Dermatology, 2021, 84, 273-282.	0.6	7
790	Teriflunomide-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. Clinical and Experimental Dermatology, 2021, 46, 166-169.	0.6	4

#	Article	IF	CITATIONS
791	Terbinafineâ€induced DRESS syndrome mimicking eosinophilic cellulitis. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e145-e147.	1.3	1
792	Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management. Journal of Cutaneous Medicine and Surgery, 2021, 25, 59-76.	0.6	90
793	Cutaneous Drug Reactions With Systemic Features. , 2021, , 743-752.e4.		0
794	Antibacterial antibiotic-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a literature review. European Journal of Clinical Pharmacology, 2021, 77, 275-289.	0.8	49
795	A Nationwide Study of Severe Cutaneous Adverse Reactions Based on the Multicenter Registry in Korea. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 929-936.e7.	2.0	18
796	Benralizumab for severe DRESS in two COVID-19 patients. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 481-483.e2.	2.0	25
797	The risk of antiâ€osteoporotic agentâ€induced severe cutaneous adverse drug reactions and their association with HLA. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 712-720.	1.3	8
798	Case of vitiligo universalis as a sequela of drugâ€induced hypersensitivity syndrome. Journal of Dermatology, 2021, 48, 92-95.	0.6	3
799	Delayed hypersensitivity to antiepileptic drugs in children. Pediatric Allergy and Immunology, 2021, 32, 425-436.	1.1	10
800	Raltegravir-associated Drug-Reaction With Eosinophilia and Systemic Symptoms Syndrome in a Pediatric Patient Without Characteristic Human Leukocyte Antigen B*57:01 or B*53:01 alleles. Journal of the Pediatric Infectious Diseases Society, 2021, 10, 363-366.	0.6	1
801	Systematic review of BRAF/MEK inhibitorsâ€induced Severe Cutaneous Adverse Reactions (SCARs). Journal of the European Academy of Dermatology and Venereology, 2021, 35, 607-614.	1.3	26
802	Drug Rash With Eosinophilia and Systemic Symptoms (DRESS) Syndrome Probably Related to Cefpodoxime: A Case Report. Journal of Pharmacy Practice, 2021, 34, 163-165.	0.5	7
803	Antipsychotic-Induced Drug Rash With Eosinophilia and Systemic Symptoms Syndrome: A Case Report. American Journal of Therapeutics, 2021, 28, e253-e254.	0.5	2
805	Severe acute generalized exanthematous pustulosis (<scp>AGEP</scp>) induced by miconazole oral gel with overlapping features of drug reaction with eosinophilia and systemic symptoms (<scp>DRESS</scp>). Contact Dermatitis, 2021, 84, 474-476.	0.8	9
806	An Updated Review of the Diagnostic Methods in Delayed Drug Hypersensitivity. Frontiers in Pharmacology, 2020, 11, 573573.	1.6	32
807	Drug Reaction with Eosinophilia and Systemic Symptoms and Agranulocytosis Presenting as Cervical Lymphadenopathy. Hospital Pharmacy, 2022, 57, 001857872199089.	0.4	1
808	When fever is more than infection: two cases of vancomycin-induced drug reaction with eosinophilia and systemic symptoms (DRESS). BMJ Case Reports, 2021, 14, e238006.	0.2	3
809	Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): A case with adverse reaction to three drugs alternately administered. Journal of Advanced Pediatrics and Child Health, 2021, 4, 001-005.	0.2	0

# 810	ARTICLE Severe Cutaneous Adverse Reactions Caused by Anti-Tubercular Drugs. Allergy, Asthma and	IF 1.1	CITATIONS
810	Immunology Research, 2021, 13, 173. Severe Cutaneous Adverse Reactions to Anti-tuberculosis Drugs in Korean Patients. Allergy, Asthma and Immunology Research, 2021, 13, 245.	1.1	13
813	Hypersensitivity reactions to multiple anti-tuberculosis drugs. PLoS ONE, 2021, 16, e0246291.	1.1	8
814	Drug rash with eosinophilia and systemic symptoms complicated by haemophagocytic lymphohistiocytosis: is screening required?. Clinical and Experimental Dermatology, 2021, 46, 920-922.	0.6	2
815	Alopecia universalis following DRESS, where rarities merge. Dermatologic Therapy, 2021, 34, e14842.	0.8	3
816	An unusual case of piperacillin-tazobactam-induced fever, eosinophilia, thrombocytopenia and liver damage. European Journal of Hospital Pharmacy, 2022, 29, e91-e94.	0.5	4
817	COVIDâ€19â€induced toxic epidermal necrolysis. Clinical and Experimental Dermatology, 2021, 46, 927-929.	0.6	14
818	DRESS syndrome induced by antibiotic-loaded bone cements and a diagnostic algorithm for related delayed-type hypersensitivity reactions. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1029-1031.e1.	2.0	3
819	Current Perspective Regarding the Immunopathogenesis of Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms (DIHS/DRESS). International Journal of Molecular Sciences, 2021, 22, 2147.	1.8	49
820	Accurate imputation of human leukocyte antigens with CookHLA. Nature Communications, 2021, 12, 1264.	5.8	21
821	Quando Tudo dÃ; Errado. Arquivos Brasileiros De Cardiologia, 2021, 116, 28-31.	0.3	0
822	Drugâ€induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic syndrome followed by transient palmoplantar keratodermaâ€ike eruption. Journal of Dermatology, 2021, 48, e207-e209.	0.6	1
823	Evaluation of drug patch tests in children. Allergy and Asthma Proceedings, 2021, 42, 167-174.	1.0	8
824	Viral rashes mimicking drug reaction with eosinophilia and systemic symptoms syndrome in children after β-lactams intake: a diagnostic challenge. European Journal of Pediatrics, 2021, 180, 2327-2332.	1.3	5
825	Massive clonal expansion of polycytotoxic skin and blood CD8 ⁺ T cells in patients with toxic epidermal necrolysis. Science Advances, 2021, 7, .	4.7	20
826	Whole-Exome Sequencing in Patients Affected by Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Reveals New Variants Potentially Contributing to the Phenotype. Pharmacogenomics and Personalized Medicine, 2021, Volume 14, 287-299.	0.4	2
827	Severe cutaneous adverse reaction associated with antiseizure medications: Diagnosis, management, and prevention. Epilepsy and Behavior, 2021, 117, 107844.	0.9	4
828	Hepatic manifestations of drug reaction with eosinophilia and systemic symptoms syndrome. Exploration of Medicine, 0, , .	1.5	0

ARTICLE IF CITATIONS Erythema Multiforme. Sultan Qaboos University Medical Journal, 2021, 21, 666-667. 829 0.3 0 Genomic Risk Factors Driving Immune-Mediated Delayed Drug Hypersensitivity Reactions. Frontiers in 1.1 Genetics, 2021, 12, 641905 Lamotrigine-induced cutaneous adverse drug reactions: A case series. Journal of Skin and Sexually 831 0.0 0 Transmitted Diseases, 0, . Posterior Reversible Encephalopathy Syndrome (PRES) and Drug-Induced Hypersensitivity Syndrome (DIHS) following Immunotherapy and BRAF/MEK Inhibition with Continued Response in Metastatic Melanoma. Case Reports in Oncological Medicine, 2021, 2021, 1-5. 0.2 Genetic Determinants in HLA and Cytochrome P450 Genes in the Risk of Aromatic Antiepileptic-Induced 833 1.1 8 Severe Cutaneous Adverse Reactions. Journal of Personalized Medicine, 2021, 11, 383. Unravelling cases of clozapine-related Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) in patients reported otherwise: A systematic review. Journal of Psychopharmacology, 2021, 35, 1062-1073. DRESS Syndrome After Lamotrigine Use in A Epilepsy Patient: A Case Report. Sakarya Medical Journal, O, , 835 0.1 0 Allopurinol hepatotoxicity is associated with human leukocyte antigen Class I alleles. Liver 836 1.9 International, 2021, 41, 1884-1893. Apalutamideâ€associated skin rash in patients with prostate cancer: Histological evaluation by skin 837 0.1 7 biopsy. IJU Case Reports, 2021, 4, 299-302. Cutaneous adverse reactions associated with antiseizure medication: clinical characteristics and implications in epilepsy treatment. Epileptic Disorders, 2021, 23, 466-475. Immune-related cutaneous adverse events due to checkpoint inhibitors. Annals of Allergy, Asthma and 839 12 0.5 Immunology, 2021, 126, 613-622. Severe drug $\hat{a}\in$ induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms in a 1 $\hat{a}\in$ month $\hat{a}\in$ old infant with trisomy 21. Journal of Dermatology, 2021, 48, E496-E497. 840 Acute generalized exanthematous pustulosis: Epidemiology, clinical course, and treatment outcomes 841 1.1 11 of patients treated in an Asian academic medical center. JAAD International, 2021, 3, 1-6. Role of Multiple Comorbidities and Therapies in Conditioning the Clinical Severity of DRESS: A Mono-Center Retrospective Study of 25 Cases. International Journal of Molecular Sciences, 2021, 22, 842 1.8 7072. Chemokines in Severe Cutaneous Adverse Reactions (SCARs). Biomolecules, 2021, 11, 847. 844 7 1.8 Eosinophils in skin diseases. Seminars in Immunopathology, 2021, 43, 393-409. 845 2.8 Neutrophils initiate and exacerbate Stevens-Johnson syndrome and toxic epidermal necrolysis. Science 846 5.8 29 Translational Medicine, 2021, 13, . Cutaneous and systemic hyperinflammation drives maculopapular drug exanthema in severely ill 847 COVIDa€19 patients. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 595-608.

#	Article	IF	CITATIONS
848	DRESS Syndrome Associated with Liposomal Amphotericin-B in a Kidney Transplant Patient: A Case Report. Current Drug Safety, 2023, 18, 264-266.	0.3	3
849	Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Series of 49 French Pediatric Cases. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 267-274.e5.	2.0	18
850	A severe presentation of acute generalized exanthematous pustulosis with nonâ€infectious circulatory shock in an adolescent. Pediatric Dermatology, 2021, 38, 1267-1271.	0.5	2
851	Liver enzyme elevation and eosinophilia with atorvastatin: a case of probable DRESS without cutaneous symptoms. Allergy, Asthma and Clinical Immunology, 2021, 17, 81.	0.9	3
852	Stevens-Johnson syndrome/toxic epidermal necrolysis in patients treated with immune checkpoint inhibitors: A safety analysis of clinical trials and FDA pharmacovigilance database. EClinicalMedicine, 2021, 37, 100951.	3.2	30
853	Association of HLA-B*51:01, HLA-B*55:01, CYP2C9*3, and Phenytoin-Induced Cutaneous Adverse Drug Reactions in the South Indian Tamil Population. Journal of Personalized Medicine, 2021, 11, 737.	1.1	6
854	Response to: Momen etÂal's "Discriminating minor and major forms of drug reaction with eosinophilia and systemic symptoms: Facial edema aligns to the severe phenotype― Journal of the American Academy of Dermatology, 2021, 85, e303-e304.	0.6	0
855	Current Perspectives on Severe Drug Eruption. Clinical Reviews in Allergy and Immunology, 2021, 61, 282-298.	2.9	23
856	Recent Advancement of Drug-Induced Hypersensitivity Syndrome. Nishinihon Journal of Dermatology, 2021, 83, 295-300.	0.0	0
857	Genetic variants associated with severe cutaneous adverse drug reactions induced by carbamazepine. British Journal of Clinical Pharmacology, 2022, 88, 773-786.	1.1	8
858	ELISpot assay as a diagnostic tool in drug hypersensitivity reactions. Journal of Immunological Methods, 2021, 495, 113062.	0.6	11
859	Carbamazepine induced toxic epidermal necrolysis and Stevens-Johnson syndrome overlapping during pregnancy in a South-East Asian patient: A case report. Annals of Medicine and Surgery, 2021, 68, 102616.	0.5	3
860	Cephalosporin-Induced Atypical DRESS Syndrome; a Tale of Two Cases. Journal of Skin and Stem Cell, 2021, 8, .	0.1	0
861	DRESS and AGEP Reactions to Iodinated Contrast Media: A French Case Series. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3041-3050.	2.0	15
862	Impact of systemic to topical steroids switch on the outcome of drug reaction with eosinophilia and systemic symptoms (DRESS): A monocenter retrospective study of 20 cases. Annales De Dermatologie Et De Venereologie, 2021, 148, 168-171.	0.5	8
863	Less Known Gastrointestinal Manifestations of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome: A Systematic Review of the Literature. Journal of Clinical Medicine, 2021, 10, 4287.	1.0	28
864	Reply to "Benralizumab: AÂpotential tailored treatment for life-threatening DRESS in the COVID-19 era― Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3531-3532.	2.0	7
865	Benralizumab: AÂpotential tailored treatment for life-threatening DRESS in the COVID-19 era. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3529-3531.e1.	2.0	13

	Article	IF	CITATIONS
866	Discriminating minor and major forms of drug reaction with eosinophilia and systemic symptoms: Facial edema aligns to the severe phenotype. Journal of the American Academy of Dermatology, 2021, 85, 645-652.	0.6	17
867	Patch tests in nonâ€immediate cutaneous adverse drug reactions: the importance of late readings on day 4. Contact Dermatitis, 2021, , .	0.8	5
868	Specific features of amoxicillinâ€associated Drug Reaction with Eosinophilia and Systemic Symptoms syndrome: a nationwide study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 2415-2420.	1.3	4
869	Reintroduction of Antituberculous Drugs in Patients with Antituberculous Drug-Related Drug Reaction with Eosinophilia and Systemic Symptoms. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3442-3449.e3.	2.0	11
870	DRESS syndrome (drug rash with eosinophilia and systemic symptoms): sometimes, not all signs are there. Italian Journal of Medicine, 2021, 15, .	0.2	1
871	Clinical, biochemical, and serologic predictors of drug reaction with eosinophilia and systemic symptoms syndrome: A prospective case–control study. Journal of the American Academy of Dermatology, 2021, 85, 901-909.	0.6	10
872	Drug reaction with eosinophilia and systemic symptoms syndrome secondary to acetazolamide associated with markedly elevated procalcitonin. BMJ Case Reports, 2021, 14, e236966.	0.2	1
873	Severe Cutaneous Adverse Reactions. , 2009, , 473-484.		23
874	Patch Testing in Adverse Drug Reactions. , 2011, , 475-491.		12
875	Drug reaction with eosinophilia and systemic symptoms in pediatric patients: A clinicopathological study of 16 cases in the National Center of Pharmacovigilance of Tunisia. Therapie, 2019, 74, 531-535.	0.6	3
876	A precision medicine–based strategy for a severe adverse drug reaction. Nature Medicine, 2020, 26, 167-168.	15.2	6
877	HLA-Aâ^—24:02 associated with lamotrigine-induced cutaneous adverse drug reactions. Medicine (United) Tj ETQ	q110.78	4314 rgBT
878	Furosemide-Associated Drug Reaction With Eosinophilia and Systemic Symptoms. American Journal of Therapeutics, 2020, Publish Ahead of Print, .	0.5	2
879	Drug reaction with eosinophilia and systemic symptoms: A single center descriptive observational study. Dermatologic Therapy, 2021, 34, e14670.	0.8	5
880	Is this still just sarcoidosis, or should we a-DRESS a different diagnosis?. BMJ Case Reports, 2015, 2015, bcr2014207778.	0.2	1
881	DRESS syndrome presenting after initiation of <i>mycobacterium avium</i> complex osteomyelitis treatment. BMJ Case Reports, 2015, 2015, bcr2015210907.	0.2	4
882	Vancomycin-associated drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: masquerading under the guise of sepsis. BMJ Case Reports, 2017, 2017, bcr-2017-221898.	0.2	5
883	Toxic epidermal necrolysis: the red eye and red herrings in casualty. BMJ Case Reports, 2018, 2018, bcr-2018-225861.	0.2	2

#	Article	IF	CITATIONS
884	Permanent renal sequelae secondary to drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome induced by quetiapine. European Journal of Hospital Pharmacy, 2021, 28, 285-288.	0.5	3
885	Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome in a paediatric patient taking zonisamide. European Journal of Hospital Pharmacy, 2020, , ejhpharm-2020-002387.	0.5	2
886	Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Associated with <i>Mycoplasma pneumoniae</i> Infection. Case Reports in Dermatology, 2021, 12, 225-230.	0.3	2
887	Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions. Journal of Clinical Investigation, 2018, 128, 985-996.	3.9	185
888	Full-Body Rash and Fever in a 15-Year-Old Male. Clinical Pediatrics, 2020, 59, 933-937.	0.4	1
889	Acute generalized exanthematous pustulosis simulating toxic epidermal necrolysis: case presentation and literature review. Allergy, Asthma and Clinical Immunology, 2020, 16, 9.	0.9	9
890	DRESS syndrome following ciprofloxacin exposure: An unusual association. American Journal of Case Reports, 2013, 14, 526-528.	0.3	22
891	Myocarditis Associated with Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome: A Case Report and Review of the Literature. American Journal of Case Reports, 2018, 19, 978-984.	0.3	20
892	Treatment of DIHS/DRESS syndrome with combined N-acetylcysteine, prednisone and valganciclovir – a hypothesis. Medical Science Monitor, 2012, 18, CS57-CS62.	0.5	43
893	Pediatric SJS-TEN: Where are we now?. F1000Research, 2020, 9, 982.	0.8	20
894	Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis. F1000Research, 2020, 9, 612.	0.8	67
895	Liver involvement in the drug reaction, eosinophilia, and systemic symptoms syndrome. World Journal of Clinical Cases, 2019, 7, 705-716.	0.3	26
896	Comparison of a New In-House and Three Published HLA-B*15:02 Screening Methods for Prevention of Carbamazepine-Induced Severe Drug Reactions. PLoS ONE, 2016, 11, e0155907.	1.1	7
897	The Effect of Intravenous Immunoglobulin Combined with Corticosteroid on the Progression of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Meta-Analysis. PLoS ONE, 2016, 11, e0167120.	1.1	38
898	DRESS Syndrome Secondary to Carbamazepine Therapy Presenting with Bilateral Acute Anterior Uveitis and Angle Closure Glaucoma. Journal of Ophthalmic and Vision Research, 2019, 14, 382-386.	0.7	3
899	Impact of HLA-B*58:01 allele and allopurinol-induced cutaneous adverse drug reactions: evidence from 21 pharmacogenetic studies. Oncotarget, 2016, 7, 81870-81879.	0.8	29
900	HLA-B*58:01 is not the only risk factor associated with allopurinol-induced severe cutaneous adverse drug reactions. Annals of Translational Medicine, 2018, 6, S7-S7.	0.7	4
901	Clinical Phenotypes of Severe Cutaneous Drug Hypersensitivity Reactions. Current Pharmaceutical Design, 2019, 25, 3840-3854.	0.9	12

ARTICLE IF CITATIONS # Practical Approach to Children Presenting with Eosinophila and Hypereosinophilia. Current Pediatric 902 0.4 6 Reviews, 2020, 16, 81-88. DAPSONE INDUCED DRESS: A CASE REPORT. Asian Journal of Pharmaceutical and Clinical Research, 2017, 0.3 10, 4. 904 Bullous Drug Reactions. Acta Dermato-Venereologica, 2020, 100, adv00057-134. 0.6 11 Correlation Between Expression of CD134, a Human Herpesvirus 6 Cellular Receptor, on CD4+ T cells and Th2-type Immune Responses in Drug-induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms. Acta Dermato-Venereologica, 2020, 100, adv00102-2. 905 Clinical features, outcomes and treatment in children with drug induced Stevens-Johnson syndrome 906 0.2 19 and toxic epidermal necrolysis. Acta Biomedica, 2019, 90, 52-60. Delayed aminopenicillin reaction associated to human herpes virus 6 infection mimicking DRESS syndrome. Revista Alergia Mexico, 2019, 66, 375-378. Syndrome DRESS à la carbamazépine avec réactivation virale à cytomégalovirus. Medecine Intensive 908 0.1 1 Reanimation, 2018, 27, 86-90. Enzalutamide induced acute generalized exanthematous pustulosis. Journal of Dermatological Case 909 1.1 14 Reports, 2016, 10, 35-38. Slowly developing toxic epidermal necrolysis-like reaction associated with pemetrexed and 910 0.6 3 carboplatin. Ecancermedicalscience, 2020, 14, 1010. Acute tubular necrosis as a part of vancomycin induced drug rash with eosinophilia and systemic symptoms syndrome with coincident postinfectious glomerulonephritis. Korean Journal of Pediatrics, 2016, 59, 145. Dress syndrome in 7-year-old male child - case report. Medycyna Wieku Rozwojowego, 2021, 24, 45-48. 912 2 0.2 Segmental Erythema Multiforme-Like Drug Eruption by Aromatase Inhibitor Anastrozole – First Case Report and another Example of an Immunocompromised District. Open Access Macedonian Journal of 0.1 Medical Sciences, 2018, 6, 79-81. Allopurinol hypersensitivity syndrome in patients with hematological malignancies: characteristics 914 0.7 11 and clinical outcomes. Korean Journal of Internal Medicine, 2015, 30, 521. Direct costs of severe cutaneous adverse reactions in a tertiary hospital in Korea. Korean Journal of Internal Medicine, 2019, 34, 195-201. A case of a drug reaction to sulfasalazine in a patient infected with HIV. Southern African Journal of 916 3 0.3HIV Medicine, 2018, 19, 829. Acute generalized exanthematous pustulosis secondary to azathioprine. Indian Journal of 0.1 Dermatology, 2015, 60, 96. Acute generalized exanthematous pustulosis due to insect bites?. Indian Journal of Dermatology, 2015, 918 0.1 14 60, 422. Alopecia areata and vitiligo as a Long-term sequelae of drug reaction with eosinophilia and systemic 0.1 symptoms syndrome. Indian Journal of Dermatology, 2016, 61, 238.

#	Article	IF	CITATIONS
920	Oxcarbazepine induced toxic epidermal necrolysis - a rare case report. Indian Journal of Pharmacology, 2015, 47, 459.	0.4	6
921	Drug reaction with eosinophilia and systemic symptoms without skin rash. Indian Journal of Pharmacology, 2015, 47, 687.	0.4	3
922	Hydroxychloroquine-induced acute generalized exanthematous pustulosis with positive patch-testing. Indian Journal of Pharmacology, 2015, 47, 693.	0.4	14
923	DRESS syndrome with peripheral neuropathy due to reactivation of cytomegalovirus in a child. Journal of Global Infectious Diseases, 2015, 7, 89.	0.2	2
924	Lyell's syndrome and antimalarials: A case report and clinical review. Journal of Global Infectious Diseases, 2017, 9, 23.	0.2	6
925	Phenytoin-induced toxic epidermal necrolysis: Review and recommendations. Journal of Pharmacology and Pharmacotherapeutics, 2016, 7, 127-132.	0.2	9
926	Oxcarbazepine-induced drug rash with eosinophilia and systemic symptoms syndrome presenting as exfoliative dermatitis. Journal of Pharmacology and Pharmacotherapeutics, 2016, 7, 142.	0.2	6
927	Development of a scoring system using a statistical model to predict cure status in patients with cutaneous leishmaniasis. Journal of Research in Medical Sciences, 2017, 22, 1.	0.4	29
928	Acute generalized exanthematous pustulosis due to meropenem: An unusual side effect of a commonly used drug. Indian Dermatology Online Journal, 2015, 6, 446.	0.2	3
929	Diagnostic criteria for drug rash and eosinophilia with systemic symptoms. Journal of Family Medicine and Primary Care, 2017, 6, 693.	0.3	15
930	Ceftriaxone induced drug rash with eosinophilia and systemic symptoms. Journal of Research in Pharmacy Practice, 2014, 3, 72.	0.2	11
931	Clinical profile and comparison of causality assessment tools in cutaneous adverse drug reactions. Indian Dermatology Online Journal, 2019, 10, 27.	0.2	7
932	Not all febrile critical illness with rash is infective: Drug reaction may be a mimic. Indian Journal of Critical Care Medicine, 2017, 21, 229-231.	0.3	4
933	Cyclosporine in generalized bullous-fixed drug eruption. Indian Journal of Dermatology, 2018, 63, 432.	0.1	7
934	Acute generalised exanthematous pustulosis: An update. Indian Journal of Dermatology, 2018, 63, 22.	0.1	39
935	Drug reaction with eosinophilia and systemic symptoms: An update and review of recent literature. Indian Journal of Dermatology, 2018, 63, 30.	0.1	58
936	Management of Stevens-Johnson Syndrome-Toxic Epidermal Necrolysis: Looking Beyond Guidelines!. Indian Journal of Dermatology, 2018, 63, 117-124.	0.1	27
937	Bilateral acute angle closure as presenting feature of Drug Rash with Eosinophilia and Systemic Symptoms (DRESS). Indian Journal of Ophthalmology, 2019, 67, 1711.	0.5	2

#	Article	IF	CITATIONS
938	Etoricoxib-induced toxic epidermal necrolysis: A fatal case report. Indian Journal of Pharmacology, 2018, 50, 139.	0.4	10
939	Cefixime-associated acute generalized exanthematous pustulosis: Rare cases in India. Indian Journal of Pharmacology, 2018, 50, 204.	0.4	7
940	Drug reaction with eosinophilia and systemic symptoms related to antiretroviral treatment in human immunodeficiency virus patients. Indian Journal of Sexually Transmitted Diseases and AIDS, 2017, 38, 163.	0.1	10
941	Drug reaction with eosinophilia and systemic symptom in a patient with pneumonia and hyperthyroidism. Journal of Research in Pharmacy Practice, 2017, 6, 130.	0.2	1
942	Severe Cutaneous Adverse Reactions to Antiepileptic Drugs: A Nationwide Registry-Based Study in Korea. Allergy, Asthma and Immunology Research, 2019, 11, 709.	1.1	19
943	Levetiracetam-Associated Acute Kidney Injury and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome. Open Journal of Nephrology, 2014, 04, 152-155.	0.0	2
944	Case Report: Acute Generalized Exanthematous Pustulosis Caused by Praziquantel. American Journal of Tropical Medicine and Hygiene, 2019, 100, 700-702.	0.6	6
945	Diphenylhydantoin Induced DRESS Syndrome: A Case Report. Journal of the Turkish Anaesthesiology & Intensive Care Society - JTAICS, 2014, 42, 46-49.	0.1	3
946	Epidemiology of cutaneous adverse drug reactions. Allergologie Select, 2017, 1, 96-108.	1.6	38
947	A 26-year-old man with ocular complications after adverse reaction to phenytoin. Digital Journal of Ophthalmology: DJO, 2016, 22, 82.	0.2	1
948	Drug Reaction With Eosinophilia and Systemic Symptoms Induced by Valproic Acid: A Case Report. Iranian Red Crescent Medical Journal, 2016, 18, e36825.	0.5	8
949	Drug Hypersensitivity Reactions in Hospital-Admitted Children: A Single Center Study in Southern Iran. Jundishapur Journal of Natural Pharmaceutical Products, 2018, 13, .	0.3	1
951	Cephalosporin-Induced Toxic Epidermal Necrolysis Treated with Intravenous Immunoglobulin. Cureus, 2015, 7, e359.	0.2	3
952	Lamotrigine-induced DRESS Syndrome Manifesting as â€~Eosinophilic Colitis': An Uncommon Presentation of a Very Uncommon Condition. Cureus, 2020, 12, e7570.	0.2	2
953	Fatal Nevirapine-Induced Toxic Epidermal Necrolysis in a HIV Infected Patient. Journal of Clinical and Diagnostic Research JCDR, 2016, 10, FD03-6.	0.8	7
954	Metolazone Associated Stevens Johnson Syndrome-Toxic Epidermal Necrolysis Overlap. Journal of Clinical and Diagnostic Research JCDR, 2016, 10, FD01-2.	0.8	5
955	DRESS syndrome: a case report. MGM Journal of Medical Sciences, 2021, 8, 312.	0.1	0
956	A Comprehensive Review of HLA and Severe Cutaneous Adverse Drug Reactions: Implication for Clinical Pharmacogenomics and Precision Medicine. Pharmaceuticals, 2021, 14, 1077.	1.7	27

#	Article	IF	CITATIONS
957	Sulfasalazine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) with concomitant acute chikungunya virus infection: possible role of new viral trigger. BMJ Case Reports, 2021, 14, e244063.	0.2	4
958	Drug Reaction with eosinophilia and systemic symptoms with alopecia universalis and vitiligo. Medicina, 2021, 54, .	0.0	1
959	Hepatic necrosis associated with drug-induced hypersensitivity syndrome. Autopsy and Case Reports, 2012, 2, 5-14.	0.2	4
960	Drug Rash with Eosinophilia and Systemic Symptoms Syndrome in a Patient on Sulfasalazine for Ulcerative Colitis. Intestinal Research, 2012, 10, 383.	1.0	1
961	Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) in an Adolescent Treated With Lamotrigine. Journal of Pediatric Pharmacology and Therapeutics, 2013, 18, 236-240.	0.3	6
963	Severe Cutaneous Adverse Reaction. Korean Journal of Medicine, 2014, 87, 665.	0.1	4
964	Acute hepatic failure due to drug-induced hypersensitivity syndrome: a case report. Journal of the Japanese Society of Intensive Care Medicine, 2015, 22, 127-131.	0.0	2
965	Drug reaction with eosinophilia and systemic symptom induced in a 9-year-old boy. Allergy Asthma & Respiratory Disease, 2016, 4, 296.	0.3	0
966	Drug Eruptions and Hypersensitivity Syndromes. , 2016, , 69-99.		0
967	Antecedent Drug Exposure Aetiology and Management Protocols in Steven-Johnson Syndrome and Toxic Epidermal Necrolysis, A Hospital Based Prospective Study. Journal of Clinical and Diagnostic Research JCDR, 2016, 10, FC01-4.	0.8	2
968	Adverse Medication Reactions. , 2017, , 439-467.		1
969	Successful treatment of DRESS syndrome with plasmapheresis during the course of sero-­‐negative autoimmune encephalitis: a case report. European Journal of Medical Case Reports, 0, , 86-91.	0.0	1
970	Non-follicular milky globules—dermoscopy saves the day. Dermatology Practical and Conceptual, 2017, 7, 35-36.	0.5	21
971	Two Catastrophes in One Patient: Drug Reaction with Eosinophilia and Systemic Symptoms and Toxic Shock Syndrome. Cureus, 2017, 9, e1359.	0.2	1
972	A case of drug-induced hypersensitivity syndrome induced by icotinib managed by intravenous immunoglobulin and systemic corticosteroids. Indian Journal of Dermatology, Venereology and Leprology, 2018, 84, 350.	0.2	3
973	Pharmacogenetics: An Important Part of Drug Development with A Focus on Its Application. International Journal of Biomedical Investigation, 2018, 1, 1-16.	0.7	20
975	Urgences dermatologiques en réanimation : infections nécrosantes de la peau et des parties molles et toxidermies graves. Medecine Intensive Reanimation, 2018, 27, 461-474.	0.1	0
976	Histopathology of Severe Drug Eruptions. , 2019, , 227-235.		0

#	Article	IF	CITATIONS
977	Severe Cutaneous Adverse Reactions: A Single-Center Retrospective Study of 173 Patients in China. Annals of Dermatology, 2019, 31, 545.	0.3	5
978	Diagnostic utility of human leukocyte antigen B*15:02 screening in severe carbamazepine hypersensitivity syndrome. Annals of Indian Academy of Neurology, 2019, 22, 377.	0.2	6
979	Allopurinol-induced DRESS complicated by hemophagocytic lymphohistiocytosis. Gazzetta Medica Italiana Archivio Per Le Scienze Mediche, 2019, 178, .	0.0	1
980	A case of drug-induced hypersensitivity syndrome with abnormally high levels of TARC and IL-5 in serum. Nihon Shoni Arerugi Gakkaishi the Japanese Journal of Pediatric Allergy and Clinical Immunology, 2019, 33, 288-294.	0.0	Ο
981	Erythema gyratum repens as a manifestation of drug reaction with eosinophilia and systemic symptoms. Indian Journal of Dermatology, 2019, 64, 77.	0.1	0
982	A New Case of DRESS Syndrome Induced by Allopürinol and Triggered by Ceftriaxon. Ankara Medical Journal, 0, , .	0.1	0
983	Drug Eruptions. Uludağ Üniversitesi Tıp Fakültesi Dergisi, 2019, 45, 231-241.	0.2	0
984	Morbiliform Rash and Fever. , 2020, , 109-113.		Ο
985	Prolonged Extracorporeal Membrane Oxygenation Support In a Patient with Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome-associated Fulminant Myocarditis – A Case Report and Literature Review. Heart International, 2020, 14, 112.	0.4	0
986	Response to intravenous immunoglobulin in a patient of drug reaction eosinophilia systemic symptom syndrome with renal involvement complicated by steroid-induced avascular necrosis of femur. Indian Journal of Drugs in Dermatology, 2020, 6, 88.	0.0	0
987	Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Presenting with Primary Diagnosis of Hepatocellular Carcinoma. Iranian Red Crescent Medical Journal, 2020, 22, .	0.5	1
988	Drug Reaction, Eosinophilia, and Systemic Symptoms (DRESS) Syndrome As a Mimicker of Spinal Infection: Awareness for Spinal Surgeons. Cureus, 2020, 12, e7503.	0.2	0
989	Dermatological Manifestations in the Intensive Care Unit: A Practical Approach. Critical Care Research and Practice, 2020, 2020, 1-12.	0.4	2
990	Severe skin eruption with features of drug reaction with eosinophilia and systemic symptoms (DRESS) during vemurafenib treatment of melanoma. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	1.3	0
991	Cutaneous Disorders of the External Ear. , 2022, , 793-880.		0
992	Serum Soluble OX40 as a Diagnostic and Prognostic Biomarker for Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 558-565.e4.	2.0	10
993	Drug Hypersensitivity Reactions. Emergency Medicine Clinics of North America, 2022, 40, 39-55.	0.5	15
995	Potentially life‑threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review). Oncology Reports, 2020, 45, 891-898.	1.2	6

#	Article	IF	CITATIONS
996	DRESS Syndrome- Uncommon Drug Reaction with Common Disease Treatment: A Case Report. Journal of Microbiology and Infectious Diseases, 0, , 225-229.	0.1	0
997	The Role of <i>In Vitro</i> Detection of Drug-Specific Mediator-Releasing Cells to Diagnose Different Phenotypes of Severe Cutaneous Adverse Reactions. Allergy, Asthma and Immunology Research, 2021, 13, 896.	1.1	8
998	Cutaneous Disorders of the External Ear. , 2020, , 1-87.		0
999	A case of toxic epidermal necrolysis induced by cytomegalovirus infection followed by DRESS (drug) Tj ETQq1 1	0.784314 0.3	rgBT /Overlo
1000	Successful Treatment of Imatinib-Induced DRESS Syndrome Using Reslizumab without Cessation of Imatinib: A Case Report. Case Reports in Oncology, 2022, 14, 1548-1554.	0.3	3
1001	Drug-induced hypersensitivity syndrome caused by minodronic acid hydrate. BMC Pulmonary Medicine, 2021, 21, 350.	0.8	5
1002	Drug triggered pruritus, rash, papules, and blisters – is AGEP a clash of an altered sphingolipid-metabolism and lysosomotropism of drugs accumulating in the skin?. Lipids in Health and Disease, 2021, 20, 156.	1.2	2
1003	Drug Reaction With Eosinophilia and Systemic Symptom (DRESS) Following Rifampicin Treatment: A Case Report. Cureus, 2021, 13, e19223.	0.2	2
1004	A Rare Case of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Glimepiride, the Unlikely Culprit. MA¦dica, 2018, 13, 155-158.	0.4	0
1005	A Study of Cutaneous Adverse Drug Reactions in a Tertiary Care Center in Punjab. Indian Dermatology Online Journal, 2018, 9, 299-303.	0.2	0
1006	Epidemiology of Severe Cutaneous Adverse Drug Reaction and Its HLA Association among Pediatrics. Iranian Journal of Pharmaceutical Research, 2019, 18, 506-522.	0.3	9
1008	DRESS Syndrome Secondary to Spironolactone with Atypical Presentation. Indian Dermatology Online Journal, 2020, 11, 1022-1023.	0.2	0
1009	Updates and Insights in the Diagnosis and Management of DRESS Syndrome. Current Dermatology Reports, 2021, 10, 192-204.	1.1	27
1010	Clinical characteristics and management of acute generalized exanthematous pustulosis with haemodynamic instability. Skin Health and Disease, 2021, 1, e74.	0.7	4
1011	Lamotrigine Induced DRESS Syndrome in a Child: A Case Report and Literature Review. Children, 2021, 8, 1063.	0.6	2
1012	Critical Review of Gaps in the Diagnosis and Management of Drug-Induced Liver Injury Associated with Severe Cutaneous Adverse Reactions. Journal of Clinical Medicine, 2021, 10, 5317.	1.0	3
1013	Patient, Disease, and Drug-Related Risk Factors Associated with Phenytoin-Induced Cutaneous Adverse Drug Reactions in South Indian Epileptic Patients Current Drug Safety, 2021, 16, .	0.3	4
1014	Efficacy of addâ€on therapy with intravenous immunoglobulin in steroid hyporesponsive DRESS syndrome. Clinical and Translational Science, 2021, , .	1.5	4

#	Article	IF	CITATIONS
1015	Erosive cheilitis as an early manifestation in DRESS syndrome. Clinical Case Reports (discontinued), 2021, 9, e05123.	0.2	3
1016	Drug eruptions with novel targeted therapies – immune checkpoint and EGFR inhibitors. JDDG - Journal of the German Society of Dermatology, 2021, 19, 1621-1643.	0.4	6
1017	A case of toxic epidermal necrolysis after ChAdOx1 nCovâ€19 (AZD1222) vaccination. Australasian Journal of Dermatology, 2021, , .	0.4	6
1018	Risk of Progression to Autoimmune Disease in Severe Drug Eruption: Risk Factors and the Factor-Guided Stratification. Journal of Investigative Dermatology, 2022, 142, 960-968.e9.	0.3	9
1019	DRESS syndrome secondary to spironolactone with atypical presentation. Indian Dermatology Online Journal, 2020, 11, 1022.	0.2	1
1020	Etiopathological and clinical study of acute generalized exanthematous pustulosis: Experience from a tertiary care hospital in North India. Indian Dermatology Online Journal, 2020, 11, 391.	0.2	4
1021	Plasmacytoid dendritic cells diminution in peripheral blood is prevalent in drug reaction with eosinophilia and systemic symptoms and may precede human herpesvirus 6 reactivation. Dermatologica Sinica, 2021, 39, 175.	0.2	4
1022	A theoretical study of allopurinol drug sensing by carbon and boron nitride nanostructures: DFT, QTAIM, RDG, NBO and PCM insights. RSC Advances, 2021, 11, 38457-38472.	1.7	23
1023	Drug Allergy and Cutaneous Adverse Reactions. Handbook of Experimental Pharmacology, 2021, 268, 195-212.	0.9	2
1024	The role of frozen section in the rapid diagnosis of severe cutaneous adverse drug reactions. Indian Dermatology Online Journal, 2021, 12, 78.	0.2	1
1025	Cyclosporine in Stevens-Johnson syndrome and toxic epidermal necrolysis: Experience from a tertiary care centre of South Rajasthan. Indian Dermatology Online Journal, 2021, 12, 116.	0.2	2
1026	Factors predicting the outcome of stevens–Johnson syndrome and toxic epidermal necrolysis: A 5-year retrospective study. Indian Dermatology Online Journal, 2021, 12, 258.	0.2	4
1027	Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome induced by ceftriaxone with successful treatment — A case report and literature review. Indian Journal of Pharmacy and Pharmacology, 2022, 8, 298-300.	0.1	0
1028	Spectrum of severe cutaneous adverse drug reactions among pediatric population and management options. Indian Journal of Paediatric Dermatology, 2022, 23, 33.	0.0	0
1029	The clinical characteristics, putative drugs, and optimal management of 62 patients with stevens-johnson syndrome and/or toxic epidermal necrolysis: A retrospective observational study. Indian Dermatology Online Journal, 2022, 13, 23.	0.2	3
1031	Sindrome DRESS: da un caso clinico particolare alla rivisitazione della patologia. Medico E Bambino Pagine Elettroniche, 2022, 25, 10-16.	0.0	0
1032	"Heart in DRESS― Cardiac Manifestations, Treatment and Outcome of Patients with Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome: A Systematic Review. Journal of Clinical Medicine, 2022, 11, 704.	1.0	26
1033	Drug Triggers and Clinic of Acute Generalized Exanthematous Pustulosis (AGEP): A Literature Case Series of 297 Patients. Journal of Clinical Medicine, 2022, 11, 397.	1.0	15

#	Article	IF	CITATIONS
1034	RegiSCAR DRESS (drug reaction with eosinophilia and systemic symptoms) validation scoring system and Japanese consensus group criteria for atypical drug-induced hypersensitivity syndrome (DiHS): A comparative analysis. Indian Dermatology Online Journal, 2022, 13, 40.	0.2	12
1035	DRESS (drug reaction with eosinophilia and systemic symptoms) syndrome induced by lamotrigine in a child. Allergy Asthma & Respiratory Disease, 2022, 10, 66.	0.3	1
1036	Vesiculobullous Diseases. Medicina (Lithuania), 2022, 58, 186.	0.8	0
1037	Methazolamide Associated Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis in a Female of Caucasian Descent. Cureus, 2022, 14, e21864.	0.2	0
1038	<scp>Leflunomideâ€induced</scp> liver injury: Differences in characteristics and outcomes in Indian and <scp>US</scp> registries. Liver International, 2022, 42, 1323-1329.	1.9	7
1039	Culprit Medications and Risk Factors Associated with Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Population-Based Nested Case–Control Study. American Journal of Clinical Dermatology, 2022, 23, 257-266.	3.3	13
1040	Concomitance or consequence? Stevensâ€'Johnson syndrome in COVIDâ€'19: A case report. Experimental and Therapeutic Medicine, 2022, 23, 257.	0.8	3
1041	Patterns of Dermatological Diseases in Inpatient Consultations at King Abdulaziz Medical City, Jeddah, Saudi Arabia: An Underexploited Opportunity for Dermatology Clinical Training. Cureus, 2022, 14, e22132.	0.2	1
1042	Atypical, Levetiracetam-induced Hypersensitivity Syndrome Complicated by Fulminant Liver Failure in a Patient Undergoing Hemodialysis. Internal Medicine, 2022, 61, 2911-2916.	0.3	2
1043	Therapeutic RNA-silencing oligonucleotides in metabolic diseases. Nature Reviews Drug Discovery, 2022, 21, 417-439.	21.5	24
1044	Drug-Induced Hypersensitivity Syndrome (DIHS)/Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS): Clinical Features and Pathogenesis. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1155-1167.e5.	2.0	52
1045	Case Report: DRESS Syndrome Induced by Two Antituberculosis Drugs in an 8-Year-Old Girl. Frontiers in Pediatrics, 2022, 10, 830611.	0.9	2
1046	Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome in a Patient Taking Lamotrigine: A Case Report Based Literature Review. Cureus, 2022, 14, e22359.	0.2	0
1047	An extremely rare mucocutaneous adverse reaction following <scp>COVID</scp> â€19 vaccination: Toxic epidermal necrolysis. Dermatologic Therapy, 2022, 35, e15416.	0.8	14
1048	Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome. The Cochrane Library, 2022, 2022, CD013130.	1.5	18
1049	Does sensitization by SARS-CoV-2 immune complexes trigger DRESS syndrome?. Brazilian Journal of Infectious Diseases, 2022, 26, 102337.	0.3	3
1050	Drug Eruptions with Cases: Fixed Drug Eruption and DRESS Syndrome. Turkish Journal of Internal Medicine, 0, , .	0.3	0
1051	Immunomodulating Therapies in Acute Myocarditis and Recurrent/Acute Pericarditis. Frontiers in Medicine, 2022, 9, 838564.	1.2	24

#	Article	IF	CITATIONS
1052	Skin manifestations and clinical features of drug reaction with eosinophilia and systemic symptoms: a retrospective multicentre study of 125 patients. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1584-1592.	1.3	7
1053	Carbamazepine-induced DRESS Syndrome: A Rare Delayed Hypersensitivity Reaction. Journal of Psychiatric Practice, 2022, 28, 166-169.	0.3	2
1054	Patch testing in drug reaction with eosinophilia and systemic symptoms (<scp>DRESS</scp>): A literature review. Contact Dermatitis, 2022, 86, 443-479.	0.8	13
1055	COVID-19: A Curious Abettor in the Occurrence of Stevens-Johnson Syndrome. Cureus, 2022, 14, e23562.	0.2	1
1056	Treatment of PD-1 Inhibitor-Associated Toxic Epidermal Necrolysis: A Case Report and Brief Review. OncoTargets and Therapy, 2022, Volume 15, 345-351.	1.0	9
1057	Morbilliform Eruptions in the Hospitalized Child. Dermatologic Clinics, 2022, 40, 191-202.	1.0	1
1058	The assessment of severe cutaneous adverse drug reactions. Australian Prescriber, 2022, 45, 43-48.	0.5	7
1059	Undiagnosed and Rare Diseases in Critical Care. Critical Care Clinics, 2022, 38, 243-269.	1.0	0
1060	Stevens-Johnson syndrome in a pregnant woman who received the influenza vaccine. JAAD Case Reports, 2022, 23, 35-37.	0.4	1
1061	Challenges in the management of bilateral eyelid closure in Stevens-Johnson Syndrome. American Journal of Ophthalmology Case Reports, 2022, 26, 101473.	0.4	2
1062	A Case of Fever and Rash Following a Urinary Tract Infection. Pediatric Infectious Disease, 2021, 3, 163-164.	0.0	0
1063	Use of Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G)—(Equine) (BAT®) in Clinical Study Subjects and Patients: A 15-Year Systematic Safety Review. Toxins, 2022, 14, 19.	1.5	9
1064	DRESS syndrome with cholecystitis in a child: A case report and literature review. Therapie, 2022, 77, 622-624.	0.6	3
1065	Successful erlotinib rechallenge in an <scp> <i>EGFR</i> â€mutant </scp> metastatic <scp>nonâ€small</scp> cell lung cancer patient with <scp>afatinibâ€induced</scp> drug rash with eosinophilia and systemic symptoms: A case report. Thoracic Cancer, 2022, 13, 494-496.	0.8	3
1067	<i>Methicillin resistant staphylococcus aureus</i> ï¼^MRSA)åਝ発膿ç~経éŽä,ã«ç™ºç—‡ã⊷,ã,¹ãƒ†ãƒ systemic symptomsï¼^DRESS)ã®1例(A case report: Corticosteroid effective Drug reaction with eosinophil	ã,≇f‰ãŒ ia oarod) Tjl	E著効ã⊷ãi ETQq000r{
1068	Stevens–Johnson syndrome and toxic epidermal necrolysis: 11-year demographic clinical and prognostic characteristics. Indian Journal of Dermatology, 2022, 67, 12.	0.1	3
1069	Drug reaction with eosinophilia and systemic symptoms (<scp>DRESS</scp>) syndrome after topical use of <i>Nigella sativa</i> (black cumin) oil. Contact Dermatitis, 2022, 87, 203-204.	0.8	4
1070	Drug-Induced Severe Cutaneous Adverse Reactions: Insights Into Clinical Presentation, Immunopathogenesis, Diagnostic Methods, Treatment, and Pharmacogenomics. Frontiers in Pharmacology, 2022, 13, 832048.	1.6	17

#	Article	IF	CITATIONS
1071	The Conundrum of Lung Disease and Drug Hypersensitivityâ€like Reactions in Systemic Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2022, 74, 1122-1131.	2.9	24
1072	Genetic Association of Beta-Lactams-Induced Hypersensitivity Reactions: A Protocol for Systematic Review and Meta-Analysis. Genes, 2022, 13, 681.	1.0	1
1073	Successful Treatment of Carbamazepine-Induced Toxic Epidermal Necrolysis With Clinical Gastrointestinal Involvement: A Case Report. Frontiers in Pediatrics, 2022, 10, 834037.	0.9	1
1074	Pharmacovigilance approaches to study rare and very rare side-effects: the example of clozapine-related DiHS/DRESS syndrome. Expert Opinion on Drug Safety, 2022, 21, 585-587.	1.0	4
1078	Dapsone-induced DRESS after infliximab-induced vasculitis: a case of cerebral infarction in the context of multiple drug reactions. BMJ Case Reports, 2020, 13, e237560.	0.2	2
1083	A study of cutaneous adverse drug reactions in a tertiary care center in Punjab. Indian Dermatology Online Journal, 2018, 9, 299.	0.2	14
1085	Clinical characteristics of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: A single-center study. Asia Pacific Allergy, 2022, 12, e17.	0.6	4
1086	Purpura fulminans, TEN, and disseminated herpes simplex: An unexpected combination. Clinical Case Reports (discontinued), 2022, 10, e05784.	0.2	1
1087	Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS)/Drug-Induced Hypersensitivity Syndrome (DiHS)—Readdressing the DReSS. Biomedicines, 2022, 10, 999.	1.4	16
1089	An Updated Review of Genetic Associations With Severe Adverse Drug Reactions: Translation and Implementation of Pharmacogenomic Testing in Clinical Practice. Frontiers in Pharmacology, 2022, 13, 886377.	1.6	14
1090	Carbamazepine Induced Stevens-Johnson Syndrome That Developed into Toxic Epidermal Necrolysis: Review of the Literature. Case Reports in Dermatological Medicine, 2022, 2022, 1-4.	0.1	2
1091	Cutaneous drug reactions with systemic features. , 2013, , 747-755.e2.		1
1092	Associations of <i>HLA</i> genetic variants with carbamazepineâ€induced cutaneous adverse drug reactions: An updated metaâ€analysis. Clinical and Translational Science, 2022, 15, 1887-1905.	1.5	17
1094	Screening the European pharmacovigilance database for reports of clozapine-related DRESS syndrome: 47 novel cases. European Neuropsychopharmacology, 2022, 60, 25-37.	0.3	14
1095	Case Report: Cannabidiol-Induced Skin Rash: A Case Series and Key Recommendations. Frontiers in Pharmacology, 0, 13, .	1.6	8
1097	åﷺ1⁄2©ã³åç–«å†æ§‹ç⁻‰ç–‡å€™ç¾≇®ç—‡çжã,'å∽ã←ã¥é‡ç—‡COVID–19ã®1例(Various IRIS–like sympt Kyukyu Igakukai Zasshi, 2022, 33, 266-271.	oms follov	ving severe
1098	IFN-Î ³ ELISpot in Severe Cutaneous Adverse Reactions to First-Line Antituberculosis Drugs in an HIV Endemic Setting. Journal of Investigative Dermatology, 2022, 142, 2920-2928.e5.	0.3	6
1099	Antipsychotics Induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome: Literature Review and a Report of a Suspected Case Related to Chlorpromazine. Current Drug Safety, 2023, 18, 571-575.	0.3	3

ARTICLE IF CITATIONS 20â€fCutaneous drug reactions., 2010, , 435-443. 1100 0 Correlation between percentage of atypical lymphocytes in peripheral smear and disease severity based on internal organ involvement in drug reaction with eosinophilia and systemic symptoms. Indian Journal of Drugs in Dermatology, 2022, 8, 52. Unmasking of Metamizole-Induced Liver Injury by Simultaneous Development of Characteristic 1102 0.3 1 Agranulocytosis. Current Drug Safety, 2022, 17, . Acute Generalized Exanthematous Pustulosis Associated With a COVID-19 Infection. Pediatric 1.1 Infectious Disease Journal, O, Publish Ahead of Print, . Drug reaction with eosinophilia and systemic symptoms in patients hospitalized with Coronavirus Disease 2019: A case series from a large United States healthcare system. British Journal of 1104 1.4 3 Dermatology, 0, , . Management of Drug-Induced Epidermal Necrolysis (DEN) in Pediatric Patients: Moving from Drug-Induced Stevens–Johnson Syndrome, Overlap and Toxic Epidermal Necrolysis to a Single Unifying Diagnosis of DEN. Paediatric Drugs, 2022, 24, 307-319. 1.3 Potential Biomarker Identification by RNA-seq analysis in Antibiotic-related Drug Reaction with 1106 1.4 1 Eosinophilia and Systemic Symptoms (DRESS): a Pilot Study. Toxicological Sciences, 0, , . DRESS characteristics according to the causative medication. European Journal of Clinical 0.8 Pharmacology, 2022, 78, 1503-1510. Scoring Assessments in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Frontiers in 1108 1.2 4 Medicine, 0, 9, . Graves' disease: an uncommon cause of late sequelae following DRESS (drug reaction with) Tj ETQq1 1 0.784314 rgBT /Qverlock 1109 DRESS syndrome due to first-line antitubercular therapy – A diagnostic imbroglio!. Journal of Family 1111 1 0.3 Medicine and Primary Care, 2022, 11, 3280. A case of severe <scp>DRESS</scp> syndrome treated with therapeutic plasma exchange and intravenous immunoglobulin therapy. Journal of Clinical Apheresis, 0, , . Cefixime induced Steven Johnson syndrome: A case report from Bangladesh. Annals of Medicine and 1113 0.5 2 Surgery, 2022, 79, . Severe Toxic Epidermal Necrolysis and Drug Reaction with Eosinophilia and Systemic Symptoms 1114 0.3 Overlap Syndrome Treated with Benralizumab: A Case Report. Case Reports in Dermatology, 0, , 203-209. Implementation of HLA-B*15:02 Genotyping as Standard-of-Care for Reducing Carbamazepine/Oxcarbazepine Induced Cutaneous Adverse Drug Reactions in Thailand. Frontiers in 1115 5 1.6 Pharmacology, 0, 13, . Economic Evaluation of Multiple-Pharmacogenes Testing for the Prevention of Adverse Drug Reactions in People Living with HIV. Clinico Economics and Outcomes Research, 0, Volume 14, 447-463. When Autoimmunity â€~DRESSes up': A Case after Certolizumab Therapy. European Journal of Case 1117 0.2 1 Reports in Internal Medicine, 0, , . A fatal presentation of DRESS syndrome with multiple visceral failure mimicking septic shock. Annals of Medicine and Surgery, 2022, 79, .

#	Article	IF	CITATIONS
1119	Relapsing Course of Sulfasalazine-Induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Complicated by Alopecia Universalis and Vitiligo. Annals of the Academy of Medicine, Singapore, 2018, 47, 492-493.	0.2	12
1120	Idiosyncratic Drug-Induced Liver Injury Associated With and Without Drug Reaction With Eosinophilia and Systemic Symptoms. American Journal of Gastroenterology, 2022, 117, 1709-1713.	0.2	4
1121	A typical presentation of moxifloxacin-induced DRESS syndrome with pulmonary involvement: a case report and review of the literature. BMC Pulmonary Medicine, 2022, 22, .	0.8	2
1122	Toxic epidermal necrolysis after first dose of Pfizerâ€BioNTech (BNT162b2) vaccination with pharmacogenomic testing. Pediatric Dermatology, 2022, 39, 601-605.	0.5	7
1123	Therapeutic Management of Idiosyncratic Drug-Induced Liver Injury and Acetaminophen Hepatotoxicity in the Paediatric Population: A Systematic Review. Drug Safety, 2022, 45, 1329-1348.	1.4	9
1124	A Case of DiHSS/DRESS Syndrome-Related Acute Hepatic Failure. Turkish Journal of Pediatric Disease, 0, , 1-4.	0.0	0
1125	Drug-induced hypersensitivity syndrome induced by propylthiouracil: case report and literature review. Allergy, Asthma and Clinical Immunology, 2022, 18, .	0.9	2
1126	Drug hypersensitivity syndrome induced by sulfasalazine: A case report. Medicine (United States), 2022, 101, e30060.	0.4	3
1127	Acute generalized exanthematous pustulosis during apalutamide treatment in a patient with prostate cancer. IJU Case Reports, 2022, 5, 497-500.	0.1	2
1128	Chronic kidney disease is potentially an independent prognostic factor for death in Stevens-Johnson syndrome and toxic epidermal necrolysis patients. Frontiers in Medicine, 0, 9, .	1.2	2
1129	Mixed T Helper1/T Helper2/T Cytotoxic Profile in Subjects with Chronic Chagas Disease with Hypersensitivity Reactions to Benznidazole. Microbiology Spectrum, 0, , .	1.2	0
1130	Modafinil-induced drug reaction with eosinophilia and systemic symptoms syndrome. JAAD Case Reports, 2022, 27, 131-133.	0.4	1
1131	The association of CD4 lymphocyte count with drug hypersensitivity reaction to highly active antiretroviral therapy, trimethoprim sulfamethoxazole, and antitubercular agents in human immunodeficiency virus patients. Asia Pacific Allergy, 2022, 12, e26.	0.6	1
1132	Acute Liver Injury in the setting of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome with Cocaine as suspected culprit agent: A case report. Clinics and Research in Hepatology and Gastroenterology, 2022, 46, 102023.	0.7	2
1133	A contemporary snippet on clinical presentation and management of toxic epidermal necrolysis. Scars, Burns & Healing, 2022, 8, 205951312211223.	0.6	0
1134	Amoxicillin-clavulanate induced DRESS syndrome masquerading as red man syndrome. Journal of Family Medicine and Primary Care, 2022, 11, 3992.	0.3	3
1135	Drug-induced Hypersensitivity Syndrome Caused by Lamotrigine, a Case Report. Acta Clinica Croatica, Supplement, 2022, , .	0.1	1
1136	Cutaneous loxoscelism associated exanthem mimicking acute generalized exanthematous pustulosis. Indian Dermatology Online Journal, 2022, 13, 667.	0.2	1

#	Article	IF	CITATIONS
1137	Reacciones adversas medicamentosas cutáneas: enfoque en el servicio de urgencias. Revista De La Asociación Colombiana De DermatologÃa Y CirugÃa Dermatológica, 2022, 30, 29-46.	0.0	0
1138	Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy. Diagnostics, 2022, 12, 2091.	1.3	5
1139	Etoricoxib Induced Toxic Epidermal Necrolysis in a case of Systemic Lupus Erythematosus: A Case Report. Journal of the Nepal Medical Association, 2022, 60, 811-814.	0.1	1
1140	A Review of the Systemic Treatment of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis. Biomedicines, 2022, 10, 2105.	1.4	8
1141	A Case of Drug-induced Hypersensitivity Syndrome Due to Apalutamide with Fatal Outcome. Nishinihon Journal of Dermatology, 2022, 84, 308-311.	0.0	1
1142	Acute Generalized Exanthematous Pustulosis in a Setting of Cutaneous Lymphoma. Cureus, 2022, , .	0.2	0
1143	Probiotic effects of Lacticaseibacillus rhamnosus 1155 and Limosilactobacillus fermentum 2644 on hyperuricemic rats. Frontiers in Nutrition, 0, 9, .	1.6	5
1144	Drug rash with eosinophilia and systemic symptoms syndrome masquerading as a lymphoproliferative disorder in a young adult on immunosuppressive therapy for rheumatoid arthritis: a case report. Journal of Medical Case Reports, 2022, 16, .	0.4	1
1145	Disease severity and status in Stevens–Johnson syndrome and toxic epidermal necrolysis: Key knowledge gaps and research needs. Frontiers in Medicine, 0, 9, .	1.2	0
1146	Recurrent Leflunomide-Induced Drug Reaction With Eosinophilia and Systemic Symptom (DRESS) Syndrome Despite Prolonged Steroid Taper: A Case Report. Cureus, 2022, , .	0.2	0
1147	Extreme Hyperferritinemia: Causes and Prognosis. Journal of Clinical Medicine, 2022, 11, 5438.	1.0	5
1148	DRESS syndrome (drug reaction with eosinophilia and systemic symptoms) to voxelotor treatment of sickle cell disease Journal of Allergy and Clinical Immunology: in Practice, 2022, , .	2.0	1
1149	Reactivation of Human Herpesvirus (HHV) 6 as Etiology of Acute Liver Injury in Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) syndrome: A Case Report. Cureus, 2022, , .	0.2	1
1150	HLAâ€A*24:02 increase the risk of allopurinolâ€induced drug reaction with eosinophilia and systemic symptoms in HLAâ€B*58:01 carriers in a Korean population; a multicenter crossâ€sectional caseâ€control study. Clinical and Translational Allergy, 2022, 12, .	1.4	2
1151	Carbamazepineâ€induced liver injury in an 11â€yearâ€old female: Case report and review of the literature. Journal of Paediatrics and Child Health, 0, , .	0.4	1
1152	Utility and Safety of Skin Tests in Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS): A Systematic Review. Journal of Allergy and Clinical Immunology: in Practice, 2023, 11, 481-491.e5.	2.0	4
1153	Pneumonia caused by toxic epidermal necrolysis. Respirology Case Reports, 2022, 10, .	0.3	1
1154	Pathology of drug hypersensitivity reactions and mechanisms of immune tolerance. Clinical and Experimental Allergy, 2022, 52, 1379-1390.	1.4	2

		CITATION REPORT		
#	Article		IF	Citations
1155	Pembrolizumab-Induced Toxic Epidermal Necrolysis. Case Reports in Oncology, 2022, 15,	, 887-893.	0.3	2
1156	Drug-induced hypersensitivity syndrome with high procalcitonin levels due to piperacillin/ and meropenem: A case report. Frontiers in Medicine, 0, 9, .	tazobactam	1.2	2
1158	Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). Updates in Clinical De 2022, , 133-141.	rmatology,	0.1	0
1159	Approach to the rash from an allergy and immunology perspective. , 2022, , 471-510.			0
1160	Tools to improve the diagnosis and management of T-cell mediated adverse drug reactior in Medicine, 0, 9, .	ns. Frontiers	1.2	4
1161	Drug reaction with eosinophilia and systemic symptoms with features resembling <scp>Stevens–Johnson</scp> syndrome/toxic epidermal necrolysis related to apalutan the European Academy of Dermatology and Venereology, 2023, 37, .	nide. Journal of	1.3	3
1162	Cutaneous adverse drug eruption: the role of drug patch testing. International Journal of Dermatology, 2023, 62, 108-114.		0.5	2
1163	Patient Care Outcomes in Hospitalized Patients with Acute Generalized Exanthematous F Cross-Sectional Database Study. American Journal of Clinical Dermatology, 2023, 24, 299		3.3	3
1164	Trimethoprim-Sulfamethoxazole-Induced Drug Reaction With Eosinophilia and Systemic S (DRESS) Complicated by Acute Liver Failure. Cureus, 2022, , .	Symptoms	0.2	0
1165	LTT and HLA testing as diagnostic tools in Spanish vancomycin-induced DRESS cases: A c study. Frontiers in Pharmacology, 0, 13, .	ase-control	1.6	6
1166	Minocycline induced drug rash with eosinophilia and systemic symptoms complicated by hemophagocytic lymphohistiocytosis. JAAD Case Reports, 2023, 32, 99-101.		0.4	2
1167	Case report: Drug reaction with eosinophilia and systemic symptoms (DRESS)-induced he disorder. Frontiers in Pharmacology, 0, 13, .	emophagocytic	1.6	1
1168	Hypersensitivity reactions to small molecule drugs. Frontiers in Immunology, 0, 13, .		2.2	5
1169	Etanercept leads to a rapid recovery of a Dabrafenibâ€/Trametinibâ€associated toxic epic necrolysisâ€kike severe skin reaction. Skin Health and Disease, 0, , .	lermal	0.7	0
1170	COVID-19 Vaccine: A Common Suspect but Rare Culprit in Drug Rash With Eosinophilia a Symptoms (DRESS) Syndrome. Cureus, 2022, , .	nd Systemic	0.2	0
1171	Reacción a fármacos con eosinofilia y sÃntomas sistémicos (DRESS). DermatologÃa , 3-13.	Argentina, 2022, 28,	0.0	0
1172	Drug reaction with eosinophilia and systemic symptoms syndrome (<scp>DRESS</scp>) pancreatitis and hepatitis following <scp>Pfizerâ€BioNTech mRNA COVID</scp> â€19 vac the European Academy of Dermatology and Venereology, 2023, 37, .		1.3	3
1173	Associations of HLA-A and HLA-B with vancomycin-induced drug reaction with eosinophili systemic symptoms in the Han-Chinese population. Frontiers in Pharmacology, 0, 13, .	a and	1.6	4

#	Article	IF	CITATIONS
1174	Bioactivity and Component Analysis of Water Extract of Sophora japonica against Hyperuricemia by Inhibiting Xanthine Oxidase Activity. Foods, 2022, 11, 3772.	1.9	4
1175	The Man of a Thousand Pustules: A Case About Acute Generalized Exanthematous Pustulosis. Cureus, 2022, , .	0.2	0
1176	Pulmonary sarcoidosis: A novel sequelae of drug reaction with eosinophilia and systemic symptoms: A case report. World Journal of Clinical Cases, 0, 10, 13074-13080.	0.3	2
1177	Case Report: Toxic epidermal necrolysis associated with sintilimab in a patient with relapsed thymic carcinoma. Frontiers in Oncology, 0, 12, .	1.3	4
1178	Management and treatment outcome of <scp>DRESS</scp> patients in Europe: An international multicentre retrospective study of 141 cases. Journal of the European Academy of Dermatology and Venereology, 2023, 37, 753-762.	1.3	6
1179	Clinical and Liver Biochemistry Phenotypes, and Outcome in 133 Patients with Anti-seizure Drug-Induced Liver Injury. Digestive Diseases and Sciences, 0, , .	1.1	1
1180	An alternative model for assessing mortality risk in Stevens Johnson syndrome/toxic epidermal necrolysis using a random forests classifier: A pilot study. Frontiers in Medicine, 0, 9, .	1.2	0
1181	Immune-Mediated Adverse Drug Reactions (IM-ARDs) in the Form of Drug-Induced Immune Thrombocytopenia and Cutaneous Adverse Drug Reactions (CARD) Due to Clindamycin in an Human Immunodeficieny Virus (HIV) Patient. American Journal of Case Reports, 0, 24, .	0.3	1
1182	Unique [18F]FDG PET imaging pattern of drug-induced acute generalized exanthematous pustulosis within the SCAR-spectrum. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50, 1532-1533.	3.3	1
1183	Toxic epidermal necrosis following Sinopharm <scp>COVID</scp> â€19 vaccine (<scp>BBIBPâ€CorV</scp>): A case report and literature review. Clinical Case Reports (discontinued), 2022, 10, .	0.2	0
1184	A Comprehensive Analysis of Topiramate and Drug Reaction With Eosinophilia and Systemic Symptoms. Cureus, 2023, , .	0.2	0
1185	Publication bias in pharmacogenetics of adverse reaction to antiseizure drugs: An umbrella review and a meta-epidemiological study. PLoS ONE, 2022, 17, e0278839.	1.1	1
1186	Tozinameran (Pfizer-BioNTech COVID-19 vaccine)-induced AGEP-DRESS syndrome. Annals of the Academy of Medicine, Singapore, 2022, 51, 796-797.	0.2	5
1187	Drug-induced liver injury: An overview and update. , 2023, , .		0
1188	Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Focus on the Pathophysiological and Diagnostic Role of Viruses. Microorganisms, 2023, 11, 346.	1.6	9
1189	Multidisciplinary Treatment in Toxic Epidermal Necrolysis. International Journal of Environmental Research and Public Health, 2023, 20, 2217.	1.2	1
1190	Acute Localized Exanthematous Pustulosis (ALEP) Caused by Topical Application of Minoxidil. Journal of Clinical Medicine, 2023, 12, 831.	1.0	1
1191	Evaluation of Delayed-Type Hypersensitivity to Antineoplastic Drugs—An Overview. Cancers, 2023, 15, 1208.	1.7	0

#	Article	IF	CITATIONS
1192	An Unusual Case of Stevens-Johnson/Toxic Epidermal Necrolysis Overlap Syndrome in HER2 (Human) Tj ETQq0 0 (2023, , .	0 rgBT /Ov 0.2	verlock 10 Tf 0
1193	Successful management with ganciclovir of drug reaction with eosinophilia and systemic symptoms secondary to antituberculous drugs associated to human herpesvirus-6 reactivation. JAAD Case Reports, 2023, 34, 90-93.	0.4	2
1195	Acute generalized exanthematous pustulosis: Clinicoâ€biological profile and inducing drugs in 83 patients. Journal of the European Academy of Dermatology and Venereology, 2023, 37, .	1.3	2
1196	Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome in a Child with Cystic Fibrosis. Case Reports in Immunology, 2023, 2023, 1-6.	0.2	1
1197	Drug reactions with eosinophilia and systemic symptoms induced by immune checkpoint inhibitors: an international cohort of 13 cases. Melanoma Research, 2023, 33, 155-158.	0.6	6
1198	Post-acute phase and sequelae management of epidermal necrolysis: an international, multidisciplinary DELPHI-based consensus. Orphanet Journal of Rare Diseases, 2023, 18, .	1.2	3
1199	Exosomal <scp>microRNAs</scp> from <scp>PBMCs</scp> stimulated with culprit drugs enhanced keratinocyte cell death in <scp>Stevens–Johnson</scp> syndrome/toxic epidermal necrolysis. Journal of the European Academy of Dermatology and Venereology, 2023, 37, 1375-1384.	1.3	1
1200	DRESS syndrome due to iodinated contrast media. A case report. Allergy, Asthma and Clinical Immunology, 2023, 19, .	0.9	1
1201	Targeting IL-36 in Inflammatory Skin Diseases. BioDrugs, 2023, 37, 279-293.	2.2	13
1202	A Peculiar Case of Idiopathic Herpes-Zoster-Like Stevens-Johnson Syndrome (SJS). Cureus, 2023, , .	0.2	1
1203	A Case of Acute Generalized Exanthematous Pustulosis Induced by Ceftriaxone. Cureus, 2023, , .	0.2	0
1204	Case report: Progressive skin rash and lymphadenopathy associated with lamotrigineâ^'valproic acid combination in a bipolar adolescent. Frontiers in Pharmacology, 0, 14, .	1.6	2
1205	Older DRESS patients are more likely to have cytopenias: a retrospective cohort study. International Journal of Dermatology, 0, , .	0.5	0
1206	Terbinafine-induced Toxic Epidermal Necrolysis in Pregnancy: A Case Report. Journal of the Nepal Medical Association, 2023, 61, 379-382.	0.1	1
1207	DRESS syndrome: A literature review and treatment algorithm. World Allergy Organization Journal, 2023, 16, 100673.	1.6	13
1208	Drug Reaction With Eosinophilia and Systemic Symptoms-Associated Perimyocarditis After Initiation of Anti-tuberculosis Therapy: A Case Report. Cureus, 2023, , .	0.2	0
1219	Diagnosis and Management of Dermatologic Adverse Events from Systemic Melanoma Therapies. American Journal of Clinical Dermatology, 0, , .	3.3	0
1237	Drug Hypersensitivity Reactions. , 2023, , 229-245.		0

ARTICLE

IF CITATIONS